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I. INTRODUCTION 
1.Inflammatory bowel disease from epidemiology to malfunction of the 
immune system  
 
1.1 Epidemiology and Environmental factors 
Inflammatory bowel disease (IBD) is defined as an inappropriate immune response that 
occurs in genetically susceptible individuals as the result of a complex interaction among 
environmental factors, microbial factors, and the intestinal immune system. As a result, 
chronic intestinal inflammation involving a pathological response in both the innate and 
adaptive immune systems is produced. Crohn’s Disease (CD) and ulcerative colitis (UC) 
represent the two main forms of IBD. Even though CD and UC represent two distinct forms 
of chronic inflammation of the gastrointestinal tract and therefore have different causes and 
different pathogenic mechanisms, the factors underlying the appearance of both CD and UC 
are roughly the same, and ultimately lead to an abnormal immune reactivity which is 
responsible for damaging the gut and causing clinical manifestations [1]. Race and ethnic 
origin seem to represent risk factors for the development of IBD, since a study shows racial 
differences in disease location and extraintestinal disease complications. In particular, it was 
observed that Jewish people are more susceptible to both CD and UC. Epidemiologically, 
northern Europe, the UK and North America display the highest incidence rates and 
prevalence of CD and UC, while South America, southeast Asia, Africa and Australia are 
considered low incidence areas [2]. The demography and clinical characteristics of these 
diseases in Asia show both similarities and differences to IBD in western populations: UC is 
more common than CD, and the clinical course tends to be milder, with fever complications 
and less need for surgical procedures. The peak age of onset of UC and CD is between 15 
and 30 years. A second peak occurs between the ages of 60 and 80. The male to female ratio 
for UC is 1:1 and for CD is 1.1 -1.8:1. Since many areas with low incidence rates include 
developing countries, these data could indicate that variation in access to healthcare and its 
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quality, as well as different extents of industrialization, sanitation and hygiene together with 
other environmental factors may play a pivotal role in the eziopathogenesis of IBD. 
However, the key question in regard to IBD epidemiology that remains still unresolved is 
what causes favor the emergence of IBD in new areas of the world [3]. A large number of 
risk factors have been proposed including cigarette smoking, diet, oral contraceptives, 
appendectomy, infections and vaccinations, and perinatal and childhood factors. However, 
with the exception of cigarette smoking, none of the other factors are supported by enough 
direct evidence to be considered true risk factors [3]. The highest mortality in IBD patients 
is during the first year of disease. Moreover in long-term disease, IBD-associated chronic 
inflammation increases the risk of dysplasia and colon cancer [4]. 
 
1.2 Pathogens and Commensal Intestinal flora  
During microbial colonization, the mucosal immune system matures, and it is during this 
time that immune, or oral, tolerance is established. In IBD patients, oral tolerance to the 
microbiota is altered [5]. 
Over the past years classical infectious agents such as Chlamydia tracomatis, Escherichia 
coli, Cytomegalovirus, Saccharomyces cerevisiae, as well as others, have been proposed as 
causes of IBD, but to date this hypothesis is rather weak. In particular, Mycobacterium 
paratuberculosis as the agent of CD received considerable attention [6], but follow up 
studies attempting to confirm its presence by histological examination have all yielded 
conflicting and inconclusive results. Subsequently the finding of paramixovirus-like 
particles in CD endothelial granulomas led to the suggestion that CD could be a form of 
chronic vasculitis caused by the persistence of the measles virus in the mucosa [7], but 
subsequent studies failed to confirm this association. While the hypothesis of  pathogen-
associated IBD was failing, evidence continued to mount indicating that the indigenous 
commensal flora of the gut is the target of the immune response in IBD. Under normal 
circumstances there is an intimate interaction between commensal intestinal bacteria and the 
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immune system and this complex crosstalk is under the control of immune tolerance. 
A large body of data coming from animal models of IBD indicates that the normal enteric 
flora is needed to develop experimental colitis [8, 9]. Thus, the paradigm “no bacteria, no 
colitis” was created to underscore the central role of the intestinal microbiota in IBD 
pathogenesis. This paradigm is supported by the observation of an increased number of 
bacteria in close contact with the mucosa in IBD patients [10]. Furthermore, IBD lesions 
occur preferentially in segments with the highest concentrations of bacteria, and surgical 
diversion of the fecal stream prevents reappearance of CD whereas restoration of the fecal 
flow induces disease recurrence [11]. Finally, modulation of the enteric flora with 
antibiotics and probiotics attenuates inflammation in IBD patients, most of whom show also 
an enhanced systemic and mucosal immunological reactivity against gut bacterial antigens 
[12]. It has been proposed that this abnormal immune reactivity is the consequence of a loss 
of tolerance towards the autologous enteric flora, resulting in an inappropriate immune 
response in the mucosa that is manifested by the chronic inflammatory process typical of 
CD and UC [13]. Why tolerance is lost and an abnormal response to otherwise normal gut 
bacteria develops in IBD is still not entirely clear.  
 
1.3 Genetic factors 
Technological advances in DNA analysis and sequencing and the use of multicenter 
databases have allowed screening for IBD-associated genetic mutations, confirming the 
theory of genetic susceptibility of both CD and UC. A number of studies has demonstrated 
clustering of cases of UC or CD within the same family, suggesting that patients share a 
genetic background. In the last years, several studies have been carried out to reveal the 
frequency of familial occurrence of IBD and the prevalence of IBD among first relatives. 
Epidemiological studies have shown that, in 75-80% of families with members affected by 
the disease, affected individuals are concordant for disease type, with all affected 
individuals having CD or, in distinct families, all ulcerative colitis affected individuals. The 
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remaining 20% of multiple affected families are mixed in which one member has CD and 
the other member has UC [14]. These findings suggest that a subset of genes associated with 
IBD would be common to both CD and UC, and others would be found only in one of the 
two diseases. It was recently discovered that 10-15% CD patients carry homozygous 
mutations in the CARD15 gene [15, 16]. Strictures, early onset of disease and/or fistulas are 
more common in patients carrying these mutations. CARD15 gene encodes a protein 
(nucleotide-binding-oligomerization-domains 2, NOD2) involved in bacterial recognition. 
Thus, defective mechanisms of bacterial sensing ( i. e. due to mutations in CARD15 gene 
which result in a protein product that no longer interacts with muramyl dipeptide (MDP) 
[17]) could represent the link between the gut flora and altered immune response found in 
IBD [18]. However, CARD15 represents only one of the genes underlying IBD 
susceptibility loci that were identified. Indeed, it has been demonstrated that genetic 
susceptibility is also important both in initiating and perpetuating chronic inflammation, 
which characterizes CD and UC. Besides CARD15, other genes, recently reported to be 
linked with the onset of IBD, are represented by MDR-1, SLC22A4/5 (which encode 
OCTN1/2) and DLG5. Furthermore, results from genome wide scans have evidenced a 
strong gene association in both forms of IBD with the gene encoding IL-23R. The 
engagement of IL-23 by its receptor, results in the activation and nuclear translocation of 
STAT3 transcription factor as well as STAT4 and STAT5 which have central roles in the 
differentiation of Th17 and Th1 cells [19]. The characterization of additional IBD 
susceptibility genes could potentially lead to the identification of novel therapeutic agents 
for IBD, and potentially allow for the molecular reclassification of the disease, and increase 
the understanding of the environmental factors contributing to intestinal inflammation. 
 
1.4 Altered intestinal homeostasis 
Increasing evidences have revealed that both human IBD and experimental colitis in mice 
are associated with immune activation in all gut-associated lymphoid tissue (GALT) organs 
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at very early stages of disease, suggesting a predominant role of these structures during the 
inflammatory process. The GALT consists of different organs, including Peyer’s patches 
(PP), isolated lymphoid follicles (ILF), cryptopatches (CP) and mesenteric lymph nodes 
(MLN). There is endoscopic and histological evidence that the earliest observable lesions in 
ileal CD are located in the follicle-associated epithelium (FAE) overlying lymphoid follicles 
and PPs, which are an inductive site of the mucosal immune system [20]. Therefore, PPs 
and Microfold cells (M cells), which transport organisms and particles from the gut lumen 
to immune cells across the epithelial barrier and thus stimulate mucosal immunity, have 
been regarded as potential sites of the inflammatory onset in CD [21]. Thus, interaction 
between luminal antigens and microorganisms with epithelial cells and dendritic cells at the 
FAE may be a crucial step in the initiation of the inflammation in CD. Preliminary findings 
suggest increased transmucosal passage of nonpathogenic E. Coli in the FAE of non-
inflamed ileum of CD, despite a normal permeability to protein antigens [22]. A previously 
unrecognized specific defect in the barrier to commensal bacteria may lead to increased 
crosstalk between luminal bacteria and the inductive sites of the mucosal immune system. 
The universal barrier dysfunction seen in CD and discussed later in this paragraph, may be 
generated by signals initiated by immune-antigen interactions in the FAE. Therefore, the 
observed diminished barrier function in the FAE may represent a very early step in mucosal 
inflammation, leading to the initiation of CD. 
There is a reduction in epithelial resistance and an increase in permeability of the inflamed 
and non-inflamed mucosa in both CD and UC [23]. In physiological conditions, the 
intestinal epithelium must function as a selective barrier to limit penetration of antigens to 
the mucosal immune system for the purpose of generating oral tolerance responses to food 
antigens or commensal organisms and host defense responses against pathogens. Epithelial 
cells lining the gastrointestinal tract are held together at the apical and basal poles by tight 
junctions that form intimate contacts to restrict the passive flow of molecules between these 
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cells. The increased epithelial permeability observed in IBD could be a consequence of 
epithelial cell apoptosis or disruption and/or down-regulation of tight-junction proteins 
exerted by activated T cells and pro-inflammatory cytokines [24-26]. In addition to 
increased permeability, epithelial cells display altered innate immune mechanisms which in 
turn reduce their ability to eliminate invasive and pathogenic microbes and lead them to 
acquire an activated phenotype, able to induce effector T cell responses [27-29]. 
Interestingly, these over-reactive or auto-reactive T cells do not undergo apoptosis once 
activated. Furthermore, mucosal dendritic cells (DC) of IBD patients lose their regulatory 
capacity, incorrectly recognizing commensal bacteria and activating immune responses 
normally directed at pathogens [30, 31]. 
 
1.5 Adaptive immune system 
After the identification of T-cells as central effector cells, and of their soluble mediators as 
key modulators of immunity, the focus of immune investigation in IBD shifted to T helper 
(Th) cell subsets and the soluble mediators that they produce. In fact in IBD, the balance of 
regulatory and effector T cells is altered. When the disease is active, effector T cells 
predominate over regulatory T cells [32, 33]; whereas in CD, intestinal CD4+ T cells 
differentiate predominantly into Th1 phenotype producing a large amount of INF-γ, IL-12, 
IL-18, which stimulate mucosal macrophages to release IL-1, TNF-a and IL-6 [34-38]. Th1 
differentiation is mediated in these patients by the marked over-expression of transcription 
factor, T-bet and the IL-23 [7, 39]. Furthermore, a persistence of auto-reactive T-cell 
populations has been reported  in both thymus and colon indicating  a failure to undergo 
apoptosis suggesting a loss of central and peripheral tolerance [40]. In contrast, patients 
with UC show an enhanced Th2 immune response with increased amounts of IL-13 and IL-
5 [41]. A few years ago IL-17-producing Th17 cells were identified as a new subset of T 
cells capable of promoting immune-mediated inflammatory responses in various tissues 
including the intestinal mucosa [42]. The discovery that this new T-cell subset drives 
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immune-mediated pathology in the gut, and that interleukin (IL)-23 amplifies Th17 cell 
responses and gut inflammation, has contributed to elucidate new pathways of tissue 
damage as well as open new avenues for the development of therapeutic strategies in IBD 
[43]. Nonetheless, it has been recently shown that Th17-related cytokines, such as IL-17A 
and IL-22, can exert protective rather than detrimental effects in the gut. Numerous studies 
in IBD patients and in animal models of colitis have demonstrated that the increased 
inflammatory infiltrate in the lamina propria (LP) reflects a consistently increased 
production of chemokines and an up-regulation of their receptors [44-53]. An array of 
chemokines have been found to be up-regulated in both CD and UC which are involved in 
the recruitment of different leukocyte subtypes into the gut mucosa, and have been proposed 
as indicators of acute phase reactivity [47, 54]. Among these chemokines, particularly 
important are IL-8, MIP-1α, MIP-1β, RANTES, MCP-1, MCP-2, and MCP-3, whose levels 
are elevated both locally and systemically, and induce conformational changes in adhesion 
molecules on lymphocytes and granulocytes. 
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Figure 1: Cytokines and T Cell Subsets in the Pathogenesis of IBD 
The T cell fate below the mucosal surface in IBD is determined by a complex interplay between 
bacterial antigens and innate immune mechanisms. Intestinal epithelial cells  and DC modulate the 
activation of the mucosal immune system by producing various cytokines and regulatory proteins. 
Based on these, signal effector T cells may differentiate into Th1, Th2, or Th17 effector T cells that 
are characterized by specific signature cytokines and transcription factors. Current evidence suggests 
that Crohn's disease is associated with an augmented Th1 and Th17 cell cytokine response, whereas 
ulcerative colitis is characterized by the production of some Th2 and Th17 cell cytokines. The 
effector T cell response in IBD is augmented by disease-perpetuating cytokines such as IL-6 and 
TNF that induce T cell activation and prevent T cell apoptosis. The aggressive T effector cell 
activation is not sufficiently counteracted by regulatory and anti-inflammatory T cells (Treg, Tr1, 
Th3 cells), thereby leading to mucosal inflammation and tissue destruction. Neurat M. F., Immunity, 
2009. 
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2. Dextran sodium sulphate (DSS): experimental model of colitis 
IBD is a complex multifactorial disease, as its pathogenesis is not limited to a unique factor, 
and cannot be reproduced in cell culture systems. In recent years the development of 
experimental animal models of IBD have significantly contributed to the present 
understanding of IBD, as they have provided a platform through which some of these 
complex mechanisms can be systematically investigated [55, 56]. There are several 
experimental models of colitis which provide different conditions for the study of factors 
involved in the pathogenesis of these diseases such as: environmental factors, the role of 
specific immune and genetic factors, and therapeutic options in IBD. They can be classified 
into four main categories  Firstly, intestinal inflammation and tissue damage can be induced 
in mice via the administration of specific chemical agents: acetic acid, dextran sodium 
sulphate (DSS) [57], trinitrobenzene sulfonic acid (TNBS) and oxazolone [58, 59]. 
Secondly, colitis develops spontaneously in a few naturally occurring mutant mouse strains: 
C3H/HeBir and SAMP1/Yit [60]. Thirdly, several gene-knockout and transgenic mouse 
strains develop colitis [61-63]. Fourthly, intestinal inflammation is observed following 
reconstitution of immunodeficient mice with CD4+ T cells [64]. The DSS model of colitis is 
the most common, quick and easily reproducible chemically induced colitis model, it has 
similarities to clinical and histological features of human IBD with UC characteristics [65]. 
The colitis is induced by the addition of DSS in drinking water. As in ulcerative colitis, 
DSS-induced colitis occurs in the distal tract of the colon provoking bleeding, diarrhoea and 
weight loss. The severity of the disease is assessed in a similar approach that used in 
humans: a disease activity index (DAI), which takes into consideration weight loss, occult 
blood in stool and stool consistency. The onset and severity of these features depends on the 
animal species, the concentration of DSS and the duration of treatment. DSS colitic mice 
show shortened oedematous colon with areas of haemorrhage and ulceration. Histologically, 
the colon presents a superficial inflammation, mainly affecting the mucosa, but may extend 
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to the submucosa and the muscularis mucosa. Superficial ulcers, goblet cell loss, crypt 
distortion and abscesses with inflammatory cell infiltration further characterize the inflamed 
mucosa of colitic mice. Colonic damage can also be macroscopically observed by 
endoscopy evaluating the presence of bleeding mucosa, altered vascular patterns, change in 
colon wall thickness and deposition of fibrin. The exact mechanism though which DSS 
initiates colitis is still unknown. One possible mechanism may be the direct alteration of gut 
permeability. Tight junction proteins responsible for paracellular permeability were directly 
reduced during DSS treatment as early as day 1, leading to the gradual increase in colonic 
inflammation. Another possible suggested mechanism is the cytotoxicity of DSS directly on 
the colonic mucosa, leading the alteration of the interaction between epithelial cells and γδ-
intraepithelial T cells [65].  
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3. Therapeutic treatment of IBD 
The quality of life for IBD patients  is lower compared to the normal population and is 
inversely related to active disease, hospitalization and surgery . Drug therapy has been 
limited to immunosuppressant and corticosteroid use until recently, with many adverse 
effects or complaints from patients. Absence of well-defined aetiological factors and unclear 
mechanisms has limited the development of new therapeutic tools. In the last years many 
studies have expanded the understanding of these diseases and fortunately new targets have 
been identified as possible new therapies in an attempt to avoid chronic steroid use, to 
prevent disease progression and to eliminate the need for surgery. Novel therapies now 
consist of monoclonal antibodies, small molecule inhibitors, peptides, and vaccines . These 
agents, collectively known as “biological” therapeutics, include recombinant peptides or 
proteins, antibody-based therapy, nucleic acid-based therapies, and cell and gene therapies 
[66]. Biological agents can be classified as inhibitors of key molecules, such as 
proinflammatory cytokines (including TNF-α), anti-inflammatory cytokines, blockers of 
cell adhesion molecules (CAMs), anti-leukocyte molecules, growth factors and 
immunostimulators, or act as inhibitors of pathologic mechanisms including Th1 
polarization, T cell activation and proliferation. Although effective in producing clinical 
response, the last approach leads to serious adverse events, and it has been therefore 
abandoned [66]. Even if several anti-tumor necrosis factor α therapies have been developed 
(Infliximab, Adalimumab, CDP571, Certolizumab) by now the only approved biologics for 
the treatment of inflammatory bowel diseases are only two, the humanized monoclonal 
antibody Infliximab and the fully human antibody Adalimumab, both used for the treatment 
of Crohn’s disease and Infliximab for the treatment of ulcerative colitis [66]. In addition to 
TNF-α, other pro-inflammatory cytokines (IL-12/IL-23 and IFN-γ), or cytokine receptors 
(IL-2R) [67-70], or downstream signaling pathways mediated by cytokines (Janus Kinase 
(JAK) 3) [71, 72] have been recently targeted, but data coming from ongoing clinical trials 
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demonstrate that their efficacy is limited. A great interest for drugs targeting other pathways 
is rinsing: Among them, the use of anti-inflammatory cytokines, like IL-10, IL-11 and IFN-
β, was tested in clinical practice, but it did not produce satisfactory results [73-75]. 
Conversely, blockers of CAMs, such as natalizumab, gave rise to great expectations, since 
they were shown to strongly inhibit the leukocyte infiltration process [76]. However, their 
clinical use has been limited, due to the increased risk of developing progressive multifocal 
leukoencephalopathy (PML) [77]. Additionally, one recent approach to the treatment of 
IBD consists of stimulators of the innate immune system, such as granulocyte colony-
stimulating factor (G-CSF), which addresses the impaired acute inflammatory response that 
results in delayed clearance of bacteria that penetrate the gut wall [78, 79]. Biologicals have 
been mainly tested in randomized controlled trials with different study designs, patient 
populations and outcome measures, making comparisons between them difficult (fig 2). 
Only a relatively small number of these biological agents have demonstrated any efficacy. 
Despite these advances, however, only a small percentage of patients benefit from these 
novel therapies, and clear limitations of the new therapeutic approaches exist. However, 
none of these treatments are curative for IBD, and a relevant number of patients are 
refractory or intolerant to many pharmacological approaches. Altered control of intestinal 
immune cell function and turnover appear to be crucial factors responsible for the 
dysregulated inflammatory response in IBD patients. Indeed, immunosuppression is a 
central component of inflammatory bowel disease treatment.Stem cell-based therapy, 
particularly that consisting of mesenchymal stem cells (MSC) transplantation, appears 
promising. Indeed, data coming from ongoing clinical trials demonstrate that intrafistular 
injections of MSC resulted in sustained complete closure as well as a reduction in CD 
activity [80]. Similarly, the use of adipose-derived MSC with fibrin glue in perianal fistulas 
promoted fistulas healing in most treated patients [81]. Despite the strong efficacy of MSC 
delivered locally in the treatment of refractory CD, therapeutic efficacy of MSC 
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systemically administered needs further investigation. 
Crohn’s Disease (CD) 
 
Ulcerative Colitis (UC) 
 
Figure 2: The therapeutic pipeline in IBD. 
Drugs are categorized based on the mechanism of action. Purple symbols indicate oral 
drugs. Danese S Gut 2012 
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4. Mesenchymal stem cells  
Adult mesenchymal stem cells (MSC) are an heterogeneous population of pluripotent 
progenitor cells that can be isolated and expanded in vitro from different tissues such as 
bone marrow, cartilage, muscle, tendon, fat and gingiva. The differentiation capacity of 
MSC along mesenchymal lineages and immunomodulatory proprieties has risen to 
enormous potential of these cells for cell-based regeneration strategies for mesenchymal 
tissue injuries and for immune disorders. Although there is a growing body of research 
focused on the potential therapeutic activity of MSC, several aspects related to their 
biological properties still remain to be elucidated.  
Adult MSC were first discovered by Friedenstein and co-workers more than 40 years ago, 
when observing bone marrow cells, the researchers have noticed within hematopoietic non-
adherent cells the presence  of a rare population of plastic-adherent cells (approximately 1 in 
10000 nucleated cells in the bone marrow). The initial clones of adherent cells expanded 
into round-shaped colonies composed of fibroblastoid cells, thus the term of Colony 
Forming Unit- fibroblasts (CFU-f) [82, 83]. Other groups then extended these initial 
observations, studying CFU-f proliferative abilities and phenotypic characteristics, and it 
was found that these cells were multipotential and could differentiate into osteoblasts, 
chondrocytes, adipocytes, and even myoblasts [84-86]. Importantly, each bone marrow 
donor shows a specific frequency of CFU-f, which is dependent on the age and health of the 
donor. Initially these cells were called either mesenchymal stem cells (MSC), for their 
ability to differentiate into cells of the mesenchymal lineages [87], or stromal cells, for their 
stromal origin. Afterwards it has been discovered that MSC cultures are heterogeneous 
displaying various grade of stemness, therefore these cells have termed  multipotent 
mesenchymal stromal cells” [88, 89]. Despite years of intense investigation, the location 
and role of the native MSC within their tissue of origin in vivo are not completely defined, 
mainly because of the lack of specific markers allowing their unambiguous identification 
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[88, 90, 91]. Thus, the possibility exists that MSC phenotype and properties vary between in 
vivo and in vitro settings due to the removal from their natural environment and the use of 
chemical and physical growth conditions that might alter their characteristics. 
 
4.1 Phenotype of mesenchymal stem cells 
The lack of specific markers that can unequivocally identify MSC and distinguish them 
from other cell types, leads in 2006 the international Society for Cell Therapy to propose the 
following criteria for the minimal identification of human MSC [92]: they have to adhere to 
plastic under standard culture conditions; they have to be positive for CD73, CD90, CD105 
and negative for CD34, CD45, HLA-DR, CD14, CD11b, CD79a, CD19 by flow cytometry; 
they have to differentiate in vitro into osteoblasts, adipocytes and chondroblasts. Although 
these criteria have started paving the way for homogeneous and unequivocal definition of 
MSC cultures, they allow once more a retrospective definition of putative MSC but do not 
allow their prospective purification. In addition, these criteria are not entirely valid across 
and intra species. Indeed, murine MSC differ frequently not only from the human MSC, but 
also among strains in marker expression and behavior in culture. To date it is widely 
accepted that human MSC express CD29, CD44, CD73, CD90, CD105, CD146 and CD166, 
while they are negative for the hematopoietic markers CD14, CD34, CD45 and CD133. In 
addition to these well-known markers, it was recently discovered that human MSC are also 
positive for CD54, CD56, CD61, CD63, CD71, CD97, CD98, CD99, CD106, CD112, 
CD155, CD276, CD304, CD325 [93], CD271 (LNGFR) and CD49a [94]. On the other 
hand, murine MSC appear negative for both the hematopoietic surface markers CD11b, 
CD34, CD45, CD117 (c-Kit), CD135 and the endothelial surface marker CD31 (PECAM-
1), while they are positive for CD29, Sca-1 and CD44. Of note, expression levels of CD90 
(Thy-1) and CD106 (VCAM-1) remain controversial, since MSC both positive and negative 
for these surface markers have been reported [95, 96]. In addition, slight differences have 
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been reported in murine MSC phenotype depending from the strain and the age of mice 
employed, the MSC tissue source, the isolation protocol and the culture conditions used. 
Importantly, since culture conditions for derivation and expansion of MSC were 
demonstrated to maintain MSC typical differentiation potency but do not preserve what is 
currently considered to be the native MSC phenotype, they seem to exert the strongest 
influence on the expression levels of MSC surface markers [91]. In addition to different 
culture conditions, mice strains from which cells are isolated deeply influence MSC 
phenotype. Indeed, it has been demonstrated that murine MSC isolated from 4 inbred strains 
show different expression levels of CD34, Sca-1 and CD106. In particular, C57Bl/6 (Bl/6) 
MSC expressed high levels of CD34, FVB/N MSC express moderate levels, and both 
Balb/C and DBA1 MSC expressed low levels.  
Many conflicting data have been published regarding the effects produced by MSC 
administration in different experimental models of human pathologies, and also data coming 
from ongoing MSC clinical trials are sometimes controversial. Further investigations are 
therefore necessary to identify specific, better unique MSC markers, which allow to obtain 
standardized MSC cultures, with well-defined in vitro characteristics that lead to predictable 
effects once used in vivo. 
 
4.2 Source and characteristics of mesenchymal stem cells 
MSC main source was represented by bone marrow. However, in the last few years many 
other sources were identified and successfully employed for MSC isolation, such as 
peripheral blood [97], cord blood [98], cord Wharton’s jelly [99], adipose tissue [100], 
amniotic fluid [101], compact bone [102], periosteum [103], synovial membrane [104], 
synovial fluid [105], articular cartilage [106] and foetal tissues [107]. Despite this 
abundance of tissue sources, MSC, especially human MSC, are mostly isolated from bone 
marrow and adipose tissue. In particular, bone marrow MSC (BM-MSC) derived from 
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aliquots of bone marrow obtained from normal donors undergoing marrow aspiration for 
purposes of allogeneic marrow transplantation, while adipose-derived MSC (A-MSC) 
derived from raw human lipoaspirates, which were digested with collagenase before plating 
in order to disaggregate tissue and obtain a single cell suspension. Importantly, since 
adipose tissue is much more accessible and abundant than bone marrow, purification of A-
MSC is easier compared to that of BM-MSC and, most important, less painful for the donor. 
For this reason, research on A-MSC properties both in vitro and in vivo has gained much 
more attention in recent years. 
BM-MSC are made up of at least 2 different subsets of cells: a population of small and 
agranular cells (RS-1) with a low proliferation capacity, and a more abundant, fast-growing 
population. It has been hypothesized that the former is represented by uncommitted 
progenitors while the latter is made up of more mature, committed progenitors. These RS-1 
cells seem to maintain the expansion potential of committed progenitors and start 
proliferating in response to factors secreted by them. Thus, BM-derived MSC cultures 
consist of an ensemble of uncommitted and committed progenitors with different degrees of 
stemness [108]. Interestingly, it was observed that bone marrow stroma feeds them into 
distant mesenchymal tissues [109]. The uncommitted MSC must leave the marrow stroma 
as such or after undergoing either self-renewal or commitment, then they should transit in 
the peripheral blood in the search of their final destination: a proper microenvironment in a 
distant tissue where they can home, expand, and further differentiate [108]. This process 
occurs during the growing period of an organism [110, 111] as well as in adult life, during 
tissue remodeling and repair in case of injury or disease [112-114]. Importantly, it has been 
shown that stem cells are usually found within specific compartments, whose maintenance 
ultimately depends on cell autonomous regulators modulated by external signals. Such 
intrinsic regulators include factors controlling cell proliferation and expression of genes 
related with the uncommitted and committed stages. In turn, extrinsic signals that control 
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stem cell fate collectively make up the stem cell microenvironment or niche, which seems to 
be essential to provide and maintain in vivo stem cells characteristics and properties [115]. 
This niche involves a complex interplay of short- and long-range signals between 
uncommitted and committed stem cells and between them and neighboring cells. Distinct 
niches were identified within the bone marrow that support hematopoietic stem cells (HSC) 
survival and growth. Indeed, bone marrow niches provide the requisite factors and adhesive 
properties to maintain HSC viability, while facilitating an appropriate balanced output of 
mature progeny for the lifetime of an organism. Current models of HSC niche advocate two 
overlapping domains: the endosteal niche near bone surfaces as the primary location of 
dormant, quiescent HSC, and the (peri)vascular niche associated with the sinusoidal 
endothelium as the primary site of dividing, self-renewing HSC [116]. In the bone marrow 
niche, MSC appear tightly associated with HSC and sympathetic nerve fibres [117]. 
 
4.3 Isolation method  
Independently from tissue sources, MSC isolation takes advantage of their capability to 
adhere to plastic when maintained in culture [118]. However, once more huge differences 
exist between human and murine MSC. Indeed, while the human MSC are easily isolated 
and extensively expanded in culture, the murine cells are far more difficult both to isolate 
and to expand. In contrast with human MSC, murine MSC cultures, especially those isolated 
from the bone marrow, are frequently contaminated by hematopoietic progenitors that 
overgrow the cultures. Furthermore, even after purification murine MSC cultures expand 
poorly [119-121]. Thus, many efforts have been made to set up new protocols for the 
isolation of murine MSC. Among them the use of monoclonal antibodies in order to pre-
select cells with a MSC surface phenotype was employed. The methods vary from negative 
selection, where other cell types, such as hematopoietic cells, are removed [96], to positive 
selection, when MSC are directly enriched from a pool of other cells in which they are 
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known to be present [94]. However, the phenotypic plasticity that MSC demonstrate in vitro 
which was previously discussed, once more point out the need for specific marker sets in 
order to obtain enrichment and, ideally, purification of MSC subsets maintaining native 
properties. 
 
4.4 Immunomodulatory properties of mesenchymal stem cells 
Beside to display multilineage differentiation capacity, MSC exert strong anti-inflammatory 
and immunosuppressive effects on the main immune cell subsets through production of 
various soluble factors or by directly interacting with target cells. Both murine and human 
MSC derived from different tissue sources are considered tolerogenic, since they express 
MHC class I but not MHC class II antigens, and they lack the expression of costimulatory 
molecules, such as CD40, CD80 and CD86 [122, 123]. However, recent studies have 
demonstrated that MSC expression of MHC class II can be modulated by IFN-γ both in 
vitro and in vivo, but whether this results in an up-regulation or a down-regulation of the 
molecule is still unclear. Indeed, many authors reported an increase of MHC class II upon 
IFN-γ stimulation, which could elicit alloreactive lymphocyte proliferative responses [124, 
125], while others showed the opposite, with high levels of IFN-γ decreasing MSC 
expression of MHC class II thereby causing loss in the ability of these cells to act as antigen 
presenting cells [126]. Thus, it is possible that MSC can change their immune suppressive 
functions according to their microenvironments, acting as immune suppressors or 
stimulators. It has been widely demonstrated that MSC exert immunomodulation by 
inhibiting the proliferation of IL-2 and IL-15 activated NK cells [127] and that of allogeneic 
lymphocytes. Indeed, MSC suppress the ex vivo expansion of γδ T cells without affecting 
their cytotoxic activity [128]. Furthermore, they can selectively abrogate the proliferation of 
CD4+ (helper) and CD8+ (cytotoxic; CTL) T cells and anti-CD40 or IL-4 stimulated B cells 
[129, 130]. Importantly, this inhibitory effect is ratio-dependent and seems to be mediated 
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mainly by production and secretion of soluble factors, such as IFN-γ [131]. Alternatively, it 
was proposed that MSC render lymphocytes anergic by a cell-to-cell contact mechanism via 
activation of PD-1/PD-L1 or PD-L2 pathway, which ultimately leads to apoptosis of T and 
B cells [132]. However, this hypothesis was subsequently contradicted by the observation 
that the proliferation of T cells efficiently resumed when restimulated with cellular or 
humoral activators in the absence of MSC [129]. Thus, so far soluble factors remain the 
most important mediators of MSC induced lymphocytes anergy. In addition to 
immunosuppression, MSC have been proved to efficiently modulate the functions of both T 
and B lymphocytes. Indeed, MSC can affect the production of both pro- and anti-
inflammatory cytokines of CD4+ and CD8+ T cells, inhibiting TNF-α and IFN-γ secretion, 
restoring IL-4 and IL-5 expression and up-regulating IL-10 expression [133]. Interestingly, 
MSC are able to suppress the differentiation of CTL precursors into CTL effectors in a dose 
and time dependent manner. Indeed, it was demonstrated that addition of MSC to mixed 
lymphocyte culture late, after CTL have reached their cytotoxic phase, fails to produce 
suppressive effects [134]. In addition, MSC were also proved effective in abrogating NK 
cell proliferation and NK cell-mediated cylolysis induced by IL-2 by down-regulating their 
surface expression of the activating receptors NKp30, NKp44 and NKG2D [127, 135]. Of 
note, since MSC express MHC class I molecule, they can be recognized as targets by 
activated CTL and NK cells. However, data regarding MSC susceptibility to be lysed by 
them are extremely controversial, since many authors demonstrated that MSC are not lysed 
by CTL and IL-2/IL-15 activated NK cells [134], while others proved the contrary [136]. 
More research is therefore necessary to investigate the susceptibility of MSC for lysis by 
immune cells, since it is essential for the efficacy and the safety of MSC therapy. As 
previously mentioned, most of MSC immunosuppressive functions are ultimately mediated 
by soluble factors, which are produced following the activation of MSC by immune cells. In 
addition to TNF-α and LPS, MSC are activated by IL-1β and IFN-γ, which are produced by 
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monocytes and activated lymphocytes or NK cells, respectively [137]. Although new 
insights in this field have been gained, the identity of soluble factors produced by MSC as 
well as the mechanisms through which they act remain unclear. Among factors with 
immunomodulatory properties, PGE2, IDO, IL-10, M-CSF, IL-6, NO, HLA-G5, HGF and 
TGF-β1 have been recently identified. Interestingly, TGF-β1 and HGF were demonstrated 
to work in a synergistic manner, blocking T cell proliferation and therefore causing 
immunosuppression [138]. Similarly, IL-10, PGE2 and NO were shown to produce 
immunosuppressive effects. In addition, PGE2 also strongly inhibits dendritic cells (DC) 
differentiation [139]. IL-6 and M-CFS were shown to retain the monocyte or macrophage 
immunophenotype (high CD14 levels and low CD1a levels), blocking their differentiation 
into DC [140]. Furthermore, the soluble isoform of the nonclassical MHC class I molecule 
HLA-G (HLA-G5) secreted by MSC was shown to inhibit the cytolytic activity of NK cells 
and CTL, to shift the T cell response to Th2 cytokine types and to induce the expansion of 
regulatory T cells (T reg) [141]. Interestingly, T reg (CD4+ CD25+ FoxP3+) represent 
specialized subsets of T cells with the capacity to suppress T cell responses, and are 
involved in both autoimmune reactions and graft rejection. MSC were demonstrated to 
increase the number of T reg both in vitro and in vivo probably through secretion of soluble 
factors. However, it is still not clear whether MSC contribute to the expansion of the already 
existing T reg, or induce new regulatory cell populations from the progenitor naïve T cells 
[122]. One of the most characterized immunosuppressive factor produced by MSC is 
represented by the enzyme indoleamine 2,3-dioxygenase (IDO). This enzyme degrades 
tryptophan, which is crucial for cell proliferation. Thus, IDO produced by MSC was 
demonstrated to block the proliferation of both T cells and NK cells, the last acting 
synergistically with PGE2 [135, 142]. Interestingly, recent findings suggest that this enzyme 
also induces generation of T reg [143]. Importantly, even though the aforementioned soluble 
factors were demonstrated to be crucial, it cannot be excluded that cell-to-cell contact also 
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contributes to provide MSC immunosuppressive functions. Indeed, it was recently 
demonstrated that the immunomodulatory effects of MSC on DC during LPS activation or 
antigen loading are dependent on cell-to-cell contact interactions. Furthermore, MSC were 
shown to down-regulate the expression of MHC class II and the costimulatory molecules 
CD80 and CD86, and decrease the secretion of IFN-γ, TNF-α, IL-2 and IL-12 by mature 
DC. This ultimately results in the modulation of the balance between Th1 and Th2 cells in 
favor of the latter [140]. It is still not clear whether these effects are produced by merely 
interaction of MSC with DC or soluble factors are also required. Of note, DC are the 
gatekeepers to the immune system of the human body, thus it seems likely that by 
suppressing the function of DC through the limitation of antigen uptake, processing or 
presentation, it could rapidly achieve a strong immunosuppression, blocking the activity of 
ideally all effector cells. Importantly, the effects of MSC on DC are reversible and thus 
avoid the complications of long-lasting hypoimmune competence following MSC 
transplantation [122]. 
	  
Figure 3: Mechanisms of MSC immunomodulation.  
Schematic representation of MSC immunomodulatory properties. Adapted from Alma J 
Blood 2007. 
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4.5 The use of mesenchymal stem cells for therapy  
Since MSC have the capacity to promote angiogenesis, differentiate to produce multiple 
types of connective tissue and down-regulate an inflammatory response, MSC have been 
extensively studied as a new therapeutic approach for many disorders. Initially MSC have 
been used in HSC transplantation, for enhancement of hematopoietic engraftment and for 
treatment/prevention of graft versus host disease [144]. Progressively  after ex vivo 
expanding, MSC have been explored to regenerate damaged tissue and treat inflammation, 
resulting from cardiovascular disease and myocardial infarction, pulmonary diseases, brain 
and spinal cord injury, stroke, diabetes, pancreatitis, cartilage and bone injury. 
Despite the beneficial properties, for clinical application, several potential risks should be 
considered, such as the immunogenicity of the cells, the biosafety of the medium 
components, the risk of ectopic tissue formation, and the potential in vitro transformation of 
the cells during expansion. Although MSC are considered to be immunoprivileged, infusion 
of allogeneic MSC into MHC-mismatched mice was recently demonstrated to induce an 
immune response, resulting in their rejection [145]. On the contrary, the infusion of 
syngeneic host-derived MSC resulted, in the same mouse model, in enhanced engraftment 
of stem cells [145]. Moreover, experimental evidences suggest that IL-2-activated 
autologous and allogeneic NK cells are capable of effectively lysing MSC, since the latter 
display ligands that are recognized by activating NK receptors that, in turn, trigger NK 
alloreactivity [146]. Despite these results, the majority of the clinical reports have suggested 
low immunogenicity of transplanted MSC in humans [80, 144]. However, on the basis of 
these experimental and clinical findings, some fundamental issues should be taken into 
consideration when determining the clinical application of MSC, including whether 
autologous or allogeneic cells should be employed, the state of immune competence of the 
patient at time of infusion, and the number of infusions needed to treat the patient. 
Importantly, since fetal calf serum (FCS) commonly used for ex vivo expansion of MSC has 
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been associated with the risk of transmission of zoonoses and potential immune reactions in 
the host [147, 148], alternative animal-free additives have been considered for clinical-grade 
expansion of MSC, such as  platelet lysate (PL)/platelet rich plasma (PRP) [149]. One of the 
potential risks of MSC treatment involves the formation of mesenchymal tissues at ectopic 
sites, as observed in an experimental model of . myocardial infarction [150], 
glomerulonephritis [151], and GvHD [152]. Beside formation of mesenchymal tissues, 
intracerebroventricular (ICV)-transplanted MSC in experimental autoimmune 
encephalomyelitis (EAE) were found migrating into the brain parenchyma and, depending 
on their density, forming cellular masses characterized by focal inflammation, 
demyelination, axonal loss and increased collagen-fibronectin deposition. These masses, 
formed by MSC at inner layers, T cells and B cells, were present only inanimals  ICV MSC-
transplanted which carried severe EAE. Importantly, the mechanism underlying the 
formation of these masses involved massive migration and subsequent  accumulation at high 
density of ICV transplanted MSC  in the brain parenchyma. Here, they may determine the 
excessive host reaction, which ultimately leads to masses formation [153]. However, despite 
these worrying results, no ectopic tissue formation has been observed following MSC 
transplantation in clinical trials, even if a strict and long-term follow-up of patients treated 
with MSC still lack.  Fortunately, it was demonstrated that human MSC of various tissue 
origin can be cultured for long period without losing their usual phenotypical/functional 
characteristics and without developing chromosomal aberrations. Indeed,  MSC malignant 
transformation in ex vivo expanded human MSC is likely to be an extremely uncommon 
event, estimated to be in the frequency of <10-9 [154]. However, a genetic characterization 
of MSC through conventional/molecular karyotyping should be considered before release of 
them for clinical application.  
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4.6 Proposed mechanisms of action involved in the efficacy of mesenchymal stem cells 
therapy  
Acute myocardial infarction  
One of the most well characterized field of application of MSC therapy is represented by 
acute myocardial infarction (MI), in which systemically delivered MSC were demonstrated 
to specifically home to injured site via SDF-1-CXCR4 interaction [155]. Indeed, CXCR4 
expressed on MSC surface binds to SDF-1, whose expression is up-regulated in 
ischemically damaged myocardium. Once engrafted, MSC strongly improved heart function 
through a number of different mechanisms operating alone or in concert. Indeed, MSC were 
shown to restore the depleted stem cell pool at the site of injury; to differentiate into 
myocytes, endothelial cells and vascular smooth muscle cells; to enhance the signaling from 
the injury site to attract more endogenous cardiac stem cells; to induce mechanical 
strengthening of the infarct scar, preventing on-going left ventricular (LV) remodeling and 
allowing endogenous repair mechanisms to improve LV function; to modulate the 
inflammatory response to acute MI, thereby limiting the amount of initial tissue damage 
[155]. In addition, MSC were shown to produce a variety of cardio-protective signaling 
molecules. Among them, insulin-like growth factor (IGF-1) released by MSC was shown to 
enhance c-Kit expression in neonatal cardiomyocytes (NCM), leading to an increase in 
NCM proliferation potential, which ultimately contributes to myocardial regeneration [155]. 
One recent study demonstrated that part of the therapeutic effects which MSC exert in MI 
could be due to their production and secretion of TNF-α stimulated gene/protein 6 (TSG-6), 
which ameliorated the clinical course of MI by decreasing both pro- and active MMP9 
levels, which leads to the reduction in granulocyte and monocyte infiltrating the ischemic 
heart [156]. 
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Pulmonary diseases 
It has demonstrated that systemically delivered MSC could be beneficial in the treatment of 
an experimental mouse asthma model, which is characterized by an allergic, Th2 dominant 
environment [157]. Indeed, when injected at the time of antigen challenge, MSC inhibited 
eosinophil infiltration and excess mucus production in the lung, decreased levels of Th2 
cytokines (IL-4, IL-5 and IL-13) in bronchial lavage, and lowered serum levels of Th2 
immunoglobulins (IgG1 and IgE). Interestingly, these effects were mediated by IL-4 and/or 
IL-13 activation of the STAT6 pathway in MSC, which results in an increase of their TGF-β 
production. In addition, MSC were also able to specifically recruit T reg in inflamed lung , 
which contribute to dampen the allergic response [157]. Recently, MSC were also found 
effective in the treatment of acute lung injury (ALI) [158]. In ALI experimental model, the 
treatment with MSC significantly reduced the expression of pro-inflammatory cytokines and 
chemokines, neutrophil counts and total protein in bronchoalveolar lavage (BAL) 24 and 
48h after LPS exposure, which leads to a reduction in pulmonary edema. Importantly, the 
anti-inflammatory effects of MSC in this experimental model of lung injury were not 
dependent on their localization to the lung, as when administered via ip they were also able 
to attenuate ALI, but on TSG-6 secretion. Indeed, knockdown of TSG-6 expression in MSC 
abrogated most of their anti-inflammatory effects, while intra-pulmonary delivery of 
recombinant human TSG-6 reduced LPS-induced inflammation in the lung similarly to 
MSC administration [158]. Finally, in a bleomycin-induced lung injury model, intravenous 
infusion of murine MSC decreased the inflammatory response to bleomycin and prevented 
the lungs from developing fibrosis [159]. The beneficial effects of MSC were largely 
explained by the cells being activated to secrete IL-1 receptor antagonist (IL-1ra), which 
inhibited the production of TNF-α by IL-1a activated macrophages. Importantly, MSC were 
effective only when administered at the same time as the bleomycin and not at later time 
points, since their action was exerted in the initial phases of the injury [159].  
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Kidney diseases 
MSC were also successfully employed for the treatment of kidney diseases. Indeed, in an 
experimental model of acute kidney injury (AKI), administration of MSC six hours after 
damage determine a reduction in the serum creatinine compared to non-treated animals 
[160]. Furthermore, the improvement in renal function was followed by a lower expression 
of IL-1β, IL-6, TNF-α and higher expression of IL-4 and IL-10, which indicates that MSC 
treatment promoted the shift from a Th1 to a Th2 inflammatory profile. Although these 
effects seem to be mediated by paracrine factors secreted by MSC, their identity remains 
unknown. Interestingly, the immunomodulatory effects exerted by MSC occur at very early 
time point, that is within 24h after their injection. Thereafter, their therapeutic efficacy 
progressively reduced, until coming to exhaustion [160]. Another study demonstrated that 
systemically injected MSC were able to induce kidney allograft tolerance [143]. Thus, 
Balb/C recipients were administered with MSC 24h after receiving a life-supporting 
orthotopic C57Bl/6 renal graft. MSC injection was proved to be effective in maintaining a 
normal histology of the transplanted kidney and undetectable antidonor antibody levels. 
Furthermore, tolerant recipients demonstrated increased circulating kynurenine levels, 
significantly high frequencies of tolerogenic DC, strongly impaired CD4+ T-cell responses 
and Th2-dominant cytokine shift. In addition, high frequencies of T reg were found both in 
recipient spleens and in donor grafts. Importantly, since MSC isolated from IDO knockout 
mice failed in achieving allograft tolerance, this soluble factor was supposed to be 
responsible, at least in part, for reduction of graft rejection, possibly through generation of T 
reg [143]. 
Rheumatoid arthritis 
In an experimental model of rheumatoid arthritis, the collagen-induced arthritis (CIA), 
human MSC delivered systemically were tested both in a prevention and treatment setting 
[161]. In both cases, MSC significantly reduced the incidence and severity of experimental 
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arthritis, inhibiting the production of various inflammatory mediators, decreasing antigen-
specific Th1/Th17 cell expansion, and inducing IL-10 secreting T reg, which, in turn, 
suppressed the self-reactive T cells. Interestingly, this study is consistent with others which 
demonstrated that after systemic administration MSC did not localize to the joints, but exert 
therapeutic effects at distance by inducing the “reset” of the immune system [161]. 
Multiple sclerosis 
In a recent study, the therapeutic effects of human MSC derived from placenta, was 
evaluated in experimental autoimmune encephalomyelitis (EAE) [162]. In this murine 
model of MS, MSC were intracerebrally transplanted 5 or 10 days after EAE induction and 
then monitored for a month. Transplanted animals displayed an increase in the survival and 
a reduction in the disease severity, compared to controls. In vitro experiments demonstrated 
that conditioned media from LPS-activated astrocytes, as well as TNF-α or IL-1β, 
stimulated MSC to express TSG-6, which could be responsible for the observed therapeutic 
effects in vivo [162]. In order to efficiently treat nervous system injury, a recent study 
investigated the possibility to enhance human MSC trophic effects by forcing them to adopt 
in vitro characteristics of Schwann cells (SC), which are known to provide trophic support 
for regenerating axons [163]. The induced MSC (sMSC) adopted a SC-like morphology, 
expressed SC-specific proteins and secreted higher amounts of several growth factors, such 
as HGF and VEGF when compared with uninduced MSC. Importantly, transplantation of 
sMSC in an ex vivo model of spinal cord injury, dramatically enhanced axonal outgrowth, 
which was mediated by HGF and VEGF secretion, and also decreased cell death [163]. 
These results demonstrated that in vitro manipulation of MSC could be a feasible approach 
to improve their therapeutic properties and therefore to better target specific pathologies.  
Corneal injury 
MSC treatment was successfully employed in a chemical and mechanical model of sterile 
injury to the cornea, where MSC administered both iv and ip were shown to reduce 
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inflammation, by decreasing neutrophil infiltration, production of pro-inflammatory 
cytokines, and development of the opacity in the cornea [164]. Importantly, MSC reduced 
inflammatory damage without engrafting into the tissue, but secreting TSG-6. Indeed, MSC 
with an siRNA knockdown of the TSG-6 gene were not effective, while systemically 
administration of recombinant human TSG-6 largely duplicated the beneficial effects of 
MSC [164]. 
Pancreatic diseases 
The therapeutic potential of this class of stem cells was also investigated in diabetes, in 
which pancreatic β islets co-cultured in vitro with either MSC or MSC conditioned medium 
(MSC-CM) demonstrated lower ADP/ATP ratios, higher glucose stimulated insulin 
secretion (GSIS) indexes and increased viability [165]. In vivo, diabetic mice that received 
islet transplants cultured in MSC-CM for 48h showed significantly lower blood glucose 
levels and enhanced blood vessel formation. Importantly, MSC were demonstrated to 
increase islet survival and function after transplantation by secreting a variety of trophic 
factors. Indeed, besides IL-6, IL-8 and TGF-β, which are mainly involved in 
immunomodulation, high levels of VEGF-A and HGF were also detected in MSC-CM 
[165]. In the field of pancreatic disorders, MSC were also studied as a stem cell-based 
therapy in an experimental model of edematous and necrotizing acute pancreatitis (AP) in 
rats [166]. Infusion of MSC 24h after the induction of the AP dampens inflammation at the 
level of histomorphology, edema, activation of digestive enzymes, and infiltration of 
inflammatory cells into the pancreas. In vivo tracking techniques revealed active homing of 
MSC to the injured pancreas, that strongly correlated with the severity of the pancreatitis. 
The mechanism proposed for such a therapeutic efficacy involved multiple aspects of the 
inflammatory response. Indeed, transfusion of MSC significantly reduced production of pro-
inflammatory cytokines and increased the production of anti-inflammatory ones, both 
locally and systemically. Furthermore, MSC specifically recruited T reg to the inflamed 
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pancreas, which are ultimately considered the mediators of the MSC induced immune 
modulation during AP [166]. 
Peritoneal injuries 
The possibility to apply MSC therapy to an experimental model of peritoneal injury, 
induced by mechanical scraping of the cecum surfaces, was also addressed [167]. Here, 
systemically injected rat MSC 24h after damage reduced adhesion formation, infiltration of 
neutrophils, macrophage proliferation and stimulated the repair of peritoneal mesothelial 
cells. Since MSC-conditioned medium reproduced the therapeutic effects of the cells, and 
MSC injected via iv mainly accumulated in the lungs, it was clear that production and 
secretion of soluble factors instead of migration and differentiation into injured cells was the 
mechanism through which MSC exert their effects. In particular, TSG-6 was identified as 
the factor that made a major contribution to the therapeutic benefits of MSC in this 
experimental model [167]. MSC therapeutic efficacy was studied also in the context of 
systemic inflammation. In particular, therapy with systemically delivered MSC was proved 
to be beneficial in the treatment of an experimental model of sepsis, induced by cecal 
ligation and puncture (CLP) [168]. Indeed, MSC administration to mice before or shortly 
after inducing sepsis reduced mortality and improved organ function. Importantly, also in 
this model MSC delivered via iv mainly localized to the lungs, where they became activated 
by TNF-α to secrete prostaglandin E2 (PGE2). PGE2, in turn, specifically interacted with 
prostaglandin EP2 and EP4 receptors expressed on macrophages, reprogramming them to a 
less inflammatory, IL-10 secreting phenotype [168]. In an experimental model of zymosan-
induced peritonitis, systemically administered human MSC were shown to significantly 
decrease the amount of neutrophils and monocytes/macrophages in the peritoneal cavity 
[169]. These anti-inflammatory effects were due to MSC secretion of TSG-6, which 
interacted with CD44 receptor on resident macrophages, decreasing zymosan/TLR2-
mediated nuclear translocation of the NF-kB, and the subsequent production and secretion 
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of the pro-inflammatory cytokines TNF-α and IL-1a. Since macrophages were the first cells 
activated to produce pro-inflammatory cytokines, their blockage by MSC through TSG-6 
production created a negative feedback loop, which attenuated the inflammatory cascade 
that is initiated by resident macrophages and then amplified by mesothelial cells and 
probably other cells of the peritoneum [169]. 
Intestinal diseases 
MSC treatment was demonstrated effective in  increasing and accelerating the recovery of 
the small intestine with reversible alterations and extended the life of animals developing 
irreversible gastrointestinal damages [170]. Importantly, MSC effects were a consequence 
of their ability to enhance or maintain the re-epithelization process, by both increasing 
endogenous proliferation and inhibiting apoptosis of intestinal epithelial cells. Furthermore, 
MSC brought about fast recovery of epithelial secretory and absorptive response, which 
were both strongly damaged by radiation, leading to the re-establishment of an anionic 
gradient across the epithelial membrane [170]. In line with this, a second study showed that 
both human and murine adipose-derived MSC significantly ameliorated the clinical and 
histopathological severity of DSS-induced colitis, abrogating weight loss, diarrhea and 
inflammation, and increasing survival [171]. These therapeutic effects were associated with 
downregulation of the Th1-driven inflammatory responses. Indeed, MSC diminished 
inflammatory infiltration in the mucosa and induced monocytes/macrophages to change 
their phenotype in a less inflammatory one, resulting in a local reduction of pro-
inflammatory cytokines and chemokines and in an increase of IL-10 production. 
Importantly, MSC were also demonstrated to induce IL-10-secreting T reg. These 
therapeutic effects seem to be completely independent from MSC homing to inflamed gut, 
since it was detected only a transient engraftment of injected cells in the intestine that 
peaked at day 2 post-injection, with 15 transplanted MSC/mg of tissue [171]. 
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4.7 Mechanisms to increase gut homing of mesenchymal stem cells 
Thus, increasing data  demonstrated that systemically delivered MSC poorly engrafted into 
injured gut,  exerting therapeutic efficacy via production and secretion of still unidentified 
soluble factors, which exert anti-inflammatory and/or trophic activities. These factors are 
produced by systemically delivered MSC far away from injured sites, especially in the 
lungs, and then reached damaged intestine via bloodstream. However, whether injected 
MSC could be specifically directed to gut, in situ production of therapeutic factors would 
probably increase both their safety and therapeutic efficacy. In particular, it was 
demonstrated that MSC cultured under sublethal hypoxic conditions increased survival and 
upregulated CXCR4 expression [172]. Since CXCL12, the ligand of CXCR4, is expressed 
in the intestine and CXCR4-expressing cells are recruited during inflammation in IBD, this 
approach could be effective in enhancing MSC gut homing in vivo. Alternatively, it was 
shown that MSC engraftment into intestine could be induced by pre-coating cells with 
antibodies [173]. In this study, MSC were treated with palmitated protein G and then coated 
with anti-VCAM-1 or MadCAM-1 antibodies. When injected into DSS-treated mice, an 
increase in VCAM-1-coated MSC engraftment occurred in the colon. Moreover, both 
MadCAM-1-coated and VCAM-1-coated MSC significantly increased survival of colitic 
mice compared to no treatment, MSC alone, or MSC co-injected with free MadCAM-1 or 
VCAM-1 antibodies.  Another valid approach, which removes the need for cell homing to 
injured site avoiding in vitro cells manipulations, is represented by local administration of 
MSC. Indeed, MSC injected into the colonic submucosa of rats previously injured with 
TNBS, were shown to decrease lesion size compared to controls [174]. Furthermore, in a 
model of ischemia-reperfusion injury, local MSC administration was shown to decrease 
pathology scores and bacterial translocation in rats [175]. In addition, local MSC injection 
in mice damaged by irradiation was found to increase their survival and histological scores 
[176]. Finally, data supporting the efficacy of local MSC transplantation for the treatment of 
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intestinal diseases come also from clinical trials, as previously described [81]. Interestingly, 
it was recently demonstrated that MSC culture conditions could also strongly influence their 
therapeutic potential. Indeed, human MSC cultured as 3D aggregates or as spheroids were 
self-activated to express anti-inflammatory proteins, such as TSG-6, stanniocalcin-1 and 
PGE2, and three anti-cancer proteins, that is IL-24, TNF-α related apoptosis inducing ligand 
(TRAIL) and CD82 [177]. Furthermore, the spheroid MSC were demonstrated to be more 
effective than MSC from adherent monolayer cultures in suppressing inflammatory 
responses both in vitro and in vivo. In addition, thanks to their reduced volume compared to 
MSC from adherent cultures, they displayed lower entrapment in the lungs after iv infusion, 
and were therefore recovered in spleen, liver, kidney and heart [177]. Thus, culturing MSC 
as spheroids could represent a valid approach to enhance both their anti-inflammatory 
properties and their engraftment into tissues. Finally, time also exert a deep impact on MSC 
therapeutic efficacy. Indeed, MSC treatment was shown to be effective in many different 
experimental models of human pathologies, including gut disorders, only when delivered 
soon after injury, since they are supposed to modulate/block the early inflammatory 
response, avoiding its propagation and perpetuation. In addition, MSC therapeutic effects 
were exerted within few hours after their injection, then they progressively reduced, until 
coming to exhaustion. Thus, despite many advances have been made in the field of MSC-
based therapy, we are still far from a detailed knowledge of MSC in vitro properties and in 
vivo behavior. One of the most important outstanding question regards the long-term fate of 
these cells once implanted, which strongly correlates with both their safety and efficacy. 
Importantly, the recent discovery that MSC therapeutic efficacy could be linked to 
production and secretion of soluble factors, instead of migration and differentiation into 
injured cells, gives rise to the possibility to move from a MSC-based therapy towards a 
factor(s)-based therapy. The latter approach would be more and more useful, since it would 
allow to set up a specific therapeutic regimen, formed by specific factor(s), depending on 
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the pathology, and to better predict both its therapeutic efficacy and its side effects. 
Furthermore, the half-life of the factor(s) in an organism would be easily determined, which 
make this kind of therapy much safer than a cell-based one. Thus, few years ago it was 
thought that MSC-based therapy would have represented the future, however the possibility 
that they could only represent a tool for the identification of new potent anti-inflammatory 
molecules which may be efficiently and safely used in therapy is now becoming more and 
more convincing. 
35 
 
 
II. OBJECTIVES  
Although the etiology is still unknown, studies have provided evidence that both forms of 
IBD are a result of a genetic predisposition that leads to a mucosal immune regulatory cell 
defect, barrier defects and susceptibility to environmental triggers, including luminal 
bacteria and specific antigens which induce to chronic gut inflammation [1, 178, 179]. The 
quality of life for IBD patients is lower compared to the normal population and is inversely 
related to active disease, hospitalization and surgery. Drug therapy has been limited to 
immunosuppressant and corticosteroid use until recently, with many adverse effects or 
complaints from patients. Absence of well-defined aetiological factors and unclear 
mechanisms have limited the development of new therapeutic tools. In the last years many 
studies have expanded the understanding of these diseases and fortunately new targets have 
been identified as possible new therapies in an attempt to avoid chronic steroid usage, to 
prevent disease progression and to eliminate the need for surgery [180]. Novel therapies 
now consist of monoclonal antibodies, small molecule inhibitors, peptides, and vaccines 
[181]. Despite these advances, however, only a small percentage of patients benefit from 
these novel therapies, and clear limitations of the new therapeutic approaches exist.  
However, none of these treatments are curative for IBD, and a relevant number of patients 
are refractory or intolerant to many pharmacological approaches. Altered control of 
intestinal immune cell function and turnover appear to be crucial factors responsible for the 
deregulated inflammatory response in IBD patients. Indeed, immunosuppression is a central 
component of inflammatory bowel disease treatment [1, 182, 183]. Clinical studies 
conducted in CD patients refractory to pharmacological treatments have demonstrated that a 
high dose of immune ablation followed by hematopoietic stem cell transplantation (HSCT) 
induced and maintained the clinical remission in these patients [184-189]. Although clinical 
reports are encouraging, however, this approach remains invasive for the patients. 
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Furthermore, it is important to consider the profound alterations in barrier function that can 
also occur as a consequence of transplantation procedures and are associated with colitis 
might predispose individuals to a more severe systemic sepsis [190]. Treatment with 
mesenchymal stem cells, on the contrary, is considered an innovative, safe, non-invasive, 
non myeloablative therapeutic approach for IBD [191, 192]. MSCs maintaining the 
pluripotent cellular capacity of multilineage differentiation, possess valuable characteristics 
for tissue repair or regeneration [170, 193]. These cells, indeed, have been shown to 
functionally integrate and remodel bone, cartilage and myocardial tissues [194-196]. In 
addition, MSCs are not immunogenic, possess the ability to modulate the immune response 
and inhibit T-lymphocyte activation [142, 197]. Accumulated data indicates that in contrast 
to the strong immunosuppressive effects induced by drugs or myeloablation, MSCs do not 
completely inhibit immune cell function. These properties could enable MCS-based therapy 
as an alternative therapeutic approach to HSC transplantation in IBD treatment.  
 Results from the phase 2 clinical trials indicate that MSC  treatment reduces the disease 
severity in Crohn’s disease patients with a positive correlation between dose and response.  
Furthermore MSCs injected directly in the site of the lesions have shown a complete closure 
of the wound without any adverse events [191, 198]. Although these clinical results are 
encouraging and promising for a future cellular therapy in the treatment of IBD, the 
molecular mechanisms underlying MSC beneficial effects have not been clarified. The 
results from multiple clinical trials using systemically administered MSC give rise to critical 
challenges that must be addressed to better understand the therapeutic potential of MSC. 
Based on this background, the objective of my thesis was to explore in experimental model 
of IBD the mechanisms through which MSC exert therapeutic efficacy in inflamed intestine. 
In order to assess the function of MSC in the treatment of IBD, I decided to divided this aim 
in two main tasks:  
1. Isolation and in vitro characterization of MSC. 
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2. Investigation of the mechanisms involving the therapeutic effects of mesenchymal 
stem cells in the inflamed gut. 
 
1. Isolation and in vitro characterization of MSC 
The first task of this study was to set up and standardize a new protocol for murine MSC 
isolation for obtaining a pure MSC population. The isolation protocols already existing and 
described in literature are based on MSC property to adhere to plastic [199, 200]. 
Unfortunately in our hand once put in culture, these cells appeared as mixed cultures, in 
which MSC coexisted with HSC, therefore the first step was to resolve this aspect 
optimizing an efficient and alternative method. So far, bone marrow represents the main 
source of MSC, even if many others have been discovered and exploited in the last years, as 
previously described [97-107]. In particular, the main disadvantage of using bone marrow to 
isolate MSC is represented by the very low frequency of the cells within it (1 MSC every 
100000/1000000 bone marrow cells). Since the adipose tissue provides one of the most 
tempting alternative source to bone marrow thanks to its accessibility, the second step of 
this task was to isolate both bone marrow (BM) and adipose (A) MSC taking advantage of 
the new protocol, and compare their in vitro properties and in vivo therapeutic effects, in 
order to choose the “best” MSC line in term of phenotype, differentiation potential, 
immunosuppressive properties and therapeutic efficacy in the treatment of experimental 
colitis. 
 
2. Investigation of the mechanisms involving the therapeutic effects of 
mesenchymal stem cells in the inflamed gut 
Given that MSC therapeutic potential is attributed to their property of specifically homing to 
damaged tissues and inhibition of inflammatory responses at target sites facilitating repair of 
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the damaged tissue [155, 166], the aim of this task is to elucidate whether MSC exert 
therapeutic efficacy by migrating into inflamed gut and differentiating into damaged cells 
therefore promoting tissue repair, or by producing and secreting soluble factors with trophic 
and/or anti-inflammatory effects, or both. 
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III. RESULTS  
 
AIM 1. Isolation and in vitro characterization of MSC 
 
Isolation of mesenchymal stem cells 
MSC isolation protocols already existing take advantage of their capability to adhere to 
plastic when maintained in culture [118]. Unfortunately once put in culture, these cells 
appeared as mixed cultures, in which MSC coexisted with HSC, therefore the first step was 
to resolve this aspect optimizing an efficient and alternative method. The possibility to use 
monoclonal antibodies in order to pre-select cells with a MSC surface phenotype by flow 
cytometric cell sorting was already explored. In particular the methods vary from negative 
selection, where other cell types, such as hematopoietic cells, are removed [96], to positive 
selection, where MSC are directly enriched from a pool of other cells in which they are 
known to be present [94]. The idea of combining negative and positive selection in a new 
cell sorting protocol comes from the need to obtain MSC culture with high degree of purity. 
For this reason MSC were sorted for Lin- and CD31- in order to eliminate hematopoietic 
and endothelial contaminants, respectively,  and for Sca-1+ to enrich the culture of stem 
cells. The only concern was represented by the high mortality rate of this technique [201]. 
However, in our experience MSC isolated utilizing this new protocol appeared vital, and 
displayed a typical MSC phenotype and bi-lineage differentiation potential. Therefore, cell 
sorting is a valid approach to isolate MSC, and the combination of positive and negative 
selection represents a successful strategy in order to obtain highly pure MSC culture. 
 
MSC isolated from bone marrow and adipose tissue displayed similar phenotypes but 
different morphology and differentiation capacity 
MSC were isolated from both bone marrow and adipose tissue of 4 to 6 week-old 
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C57BL/6N and C57BL/6-Tg(UBC-GFP)30Scha/J mice, expanded in complete MSC 
expansion medium and sorted for Lineage Cell Detection Cocktail-, CD31- and Sca-1+. 
Before sorting, the mixed population of bone marrow cells displayed high contamination of 
both hematopoietic (Lineage+) and endothelial (CD31+) cells and a very low percentage of 
MSC (0.6%, Figure 1A). On the contrary, the mixed population of adipose-tissue derived 
cells contained 96.7% of MSC and low hematopoietic and endothelial cell contamination 
(Figure 1B). 
Since it is still not possible to unequivocally identify MSC with a single surface marker, 
both sorted cells were further phenotypically characterized for surface-marker expression 
levels of a selected protein panel by flow cytometry [95, 96]. Sorted BM- and A-MSC 
expressed neither the hematopoietic surface markers Lineage Cell Detection cocktail, CD45, 
CD34 and CD117 (C-kit), nor the endothelial surface marker CD31, while both lines stained 
positive for Sca-1, CD44 and CD106 (VCAM-1) as it is possible to observe in Figure 1A 
and 1B. Interestingly, CD90 (thymocyte differentiation antigen 1 (Thy-1) marker was 
higher in A-MSC than in BM-MSC ( 72.3% versus 13%, respectively). 
BM- and A-MSC used for the experiments were from early passages after sorting, to avoid 
cellular senescence and consequent alteration of their properties [202]. Confocal analysis of 
BM- and A-MSC grown on PolyLysine pre-coated glass coverslips demonstrated that they 
displayed different morphological characteristics in terms of size and shape (Figure 1C). 
Furthermore, once put into culture and prompted to differentiate, A-MSC efficiently 
generated adipocytes after few days of culture under standard in vitro differentiating 
conditions, but they poorly differentiated into osteoblasts, even after 3 weeks of culture. On 
the contrary, BM-MSC were equally able to generate osteoblasts and adipocytes (Figure 
1C). 
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BM-MSC ameliorated DSS-induced acute colitis more efficiently than A-MSC 
MSC have already been shown to exert therapeutic efficacy in many experimental models 
for human pathologies, including chronic and acute colitis [171]. In order to compare the 
therapeutic efficacy of the two MSC lines isolated in the treatment of DSS-induced acute 
colitis, colitic mice were injected intraperitoneally with 3x106 of either BM- or A-MSC 5 
days after the beginning of DSS treatment. Colitic mice injected with saline and healthy 
mice injected with either BM- or A-MSC at day 5, respectively, represented positive and 
negative controls. BM-MSC administration considerably reduced body weight loss of colitic 
mice and significantly improved their disease activity index (DAI) starting from 48 hours 
after the injection (day 7) compared to positive control mice. Although A-MSC injection 
also promoted a reduction of body weight loss of colitic mice and an improvement in their 
DAI, it appeared less effective in ameliorating DSS-induced acute colitis compared to BM-
MSC administration. No clinical effect in terms of both body weight changes and DAI were 
detected in the negative control group (Figure 2A and 2B). At day 10 mice were sacrificed 
and colon length measurements revealed a reduction in colon shortening in colitic mice 
treated with BM-MSC compared to positive control mice, while colons of colitic mice 
injected with A-MSC displayed an intermediate length between saline and BM-MSC treated 
group (Figure 2C). A blinded pathologist scored histological sections of formalin-fixed and 
paraffin-embedded colons stained with hematoxylin and eosin. BM-MSC administration 
strongly reduced the inflammation score and the extension of DSS-induced injuries of the 
colon, while A-MSC injected mice once more displayed an intermediate inflammation score 
and grade of involvement between saline and BM-MSC treated group (Figure 2D). 
Representative images of colon sections stained with hematoxylin/eosin for each group not 
only confirmed the differences in the extension of DSS-induced injuries of the colons but 
also revealed that epithelial organization into crypts of colitic mice treated with BM-MSC 
was partially maintained, due to the presence of less inflammatory cells infiltrating the 
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tissue (Figure 2D). Although no significant differences were detected among groups in 
terms of cytokine (IL-6, TNF-α, IFN-γ, IL-10) and chemokine (RANTES, MIP-1α, KC) 
levels, BM-MSC administration partially reduced both IL-6 and KC production (Figure 2E). 
These results suggested that although phenotypically similar, MSC isolated from bone 
marrow exert in vivo more immunomodulatory effects in the treatment of experimental 
colitis compared those from adipose tissue. 
 
BM-MSC displayed in vitro a stronger immunosuppressive activity compared to A-
MSC 
It was demonstrated that MSC exert immunomodulatory properties in vitro [122]. 
Therefore, BM- and A-MSC were tested in vitro for their immunosuppressive properties by 
performing co-culture experiments with activated splenocytes (SPLs) at different 
SPLs:MSC ratios. BM-MSC efficiently inhibited proliferation of activated SPLs even when 
highly diluted (SPLs:MSC ratio 50:1), while A-MSC lost their immunosuppressive effects 
at a SPLs:MSC ratio of 10:1 and 50:1.  
Altogether the results of this aim demonstrate firstly that the combination of positive and 
negative selection allows for the obtainment of a pure and viable population of MSC 
without altering their properties. Secondly, the expression of positive marker surfaces 
including Sca-1, CD90, CD106 and CD44 on MSC is not related to activities or properties 
of MSC. Finally, the isolation source of MSC affects in vivo and in vitro 
immunomodulatory properties indicating thus that the therapeutic efficacy of these cells can 
be source-dependent. Therefore, Since BM-MSC appeared more effective than A-MSC in 
the treatment of DSS-induced colitis, we decided to focus on BM-MSC in order to clarify 
the mechanisms underlying their therapeutic efficacy. 
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AIM 2. Investigation of the mechanisms involving the therapeutic effects of mesenchymal 
stem cells in the inflamed gut  
 
BM-MSC did not engraft into the inflamed colon but remained in the peritoneal cavity 
forming cellular aggregates 
In order to follow the movements of MSC and shed light on the mechanisms by which MSC 
exert therapeutic efficacy in the treatment of DSS-induced colitis, a BM-MSC line was 
generated from C57BL/6-Tg(UBC-GFP)30Scha/J MICE. Healthy and colitic mice at day 5 
of DSS treatment were injected intraperitoneally with 3x106 GFP-MSC. Colons were 
collected 24, 48, 96 and 120 hours after the injections from all mice and analyzed for the 
expression of GFP by flow cytometry. No GFP positive cells were detected in the colon of 
colitic mice treated with saline or in the colon of healthy mice treated with GFP-MSC. 
Importantly, GFP-MSC positive cells appeared in the inflamed colon of colitic mice only at 
48 hours after injection and with a very low frequency (<1%). Furthermore, no GFP-MSC 
positive cells were found in the inflamed colon at the other time points tested (Figure 4A). 
Representative flow cytometry dot-plots at 48 hours of GFP-MSC distribution in the colons 
for each group are reported in Figure 4A. In a parallel experiment, MLNs, liver spleen and 
lungs were also investigated for the presence of engrafted GFP-MSC 24, 48, 96 and 120 
hours after the injection, but no GFP+ cells were detected at any time point tested. Poor 
engraftment of GFP-MSC into the inflamed colon was further confirmed by 
immunohistochemical analysis. Colon sections of colitic mice were stained with an antibody 
directed against GFP. Immunohistochemical staining showed that only a small amount of 
GFP+ cells were able to engraft into the inflamed gut, where they specifically localized 
either in the epithelial (Figure 4B) or endothelial cell layers (Figure 4C). 
Once the low frequency of MSC in the inflamed colon was assessed, our principal concern 
was to elucidate the MSC fate after intraperitoneal administration. For this purpose, GFP or 
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DilC18(3)-DS pre-stained MSC were injected in colitic and healthy mice. After 24, 48 and 
72 hours of injection, we performed a whole mount staining of the entire colon of treated 
mice. We observed that DilC18(3)-DS pre-stained MSC (red signal) did not egress from the 
peritoneal cavity but they aggregated within 72 hours and remained outside of the bowel 
wall vessels (in green CD31 endothelial marker) generating small aggregates. A 
representative image of a 72 hour structure is reported in Figure 5A. MSC-aggregates were 
recovered from colitic mice by peritoneal lavages 5 days after MSC administration, and they 
appeared as small high-density cell aggregates that resembled lymphoid organization both 
in shape and dimension (Figure 5B). The number and size of these aggregates were variable 
and not dependent on the inflammatory state. In order to better study their three-dimensional 
organization and cellular composition, we performed a whole mount staining of a single 
MSC aggregate. This analysis revealed that GFP-MSC formed the internal core of the MSC-
aggregates surrounded by immune cells in particular macrophages (CD68 positive) and 
lymphocytes (CD3 positive) as reported in Figure 5C. FACS analysis of these aggregates 
has further clarified the cellular types recruited from MSC. Indeed, GFP-MSC represented 
the most abundant population (74%), followed by F4/80+ macrophages (14.2%), B220+ B 
lymphocytes (9.2%), CD3+ T lymphocytes (7%) and Ly6G+ polymorphonuclear cells 
(PMN; 6.6%; Figure 5D). In order to exclude that once injected in the peritoneal cavity the 
low migratory capacity of MSC was related to their poor viability, and that consequently the 
MSC-aggregates were the result of cellular necrosis, we stained the MSC-aggregates by 
both fluorescein diacetate and ethidium bromide staining, which mark in green viable cells 
and in red those dead (Figure 5E). The viability of cells within the MSC-aggregates was 
further confirmed by the observation that once put in culture, the cells spontaneously 
detached from aggregates and adhered to culture plates as demonstrated by FACS analysis 
performed on these cells (Figure 5F-G). Indeed, gating on Lin-, CD45- and CD31- to 
exclude hematopoietic and endothelial cells, respectively, more than 50% of cells detached 
45 
 
from the structure and adhered to the plate were GFP-MSC (Figure 5G). 
In order to characterize the structure, MSC-aggregates were analyzed by two-photon 
confocal microscopy. Interestingly, this analysis  revealed a strong deposition of 
extracellular collagen fiber within the MSC-aggregates as emerged from second harmonic 
generation  signals (Figure 5H). The presence of collagen was further confirmed also by 
Sirius Red staining as reflected by red collagen fibers in Figure 5I. 
Interestingly, MSC-aggregates were observed also in healthy mice and their organization as 
well as composition was similar to those of colitic mice. 
  
BM-MSC expressed low levels of chemokine receptors and high levels of cell adhesion 
molecules  
To verify whether BM-MSC were not successful in performing gut homing for the lack of 
expression of chemokine receptors and/or adhesion molecules, we analyzed the chemokine 
receptor expression profile of MSC by RT- qPCR and the expression levels of adhesion 
molecules by flow cytometry and immunofluorescence. Interestingly, MSC expression 
levels of CCRs receptors (from 1 to 9), as well as CXCRs receptors (from 1 to 7) and 
XCR1, CX3CR1 were very low compared to those of macrophages used as a positive 
control in this experiment (Figure 6A). 
However, FACS analysis together with immunofluorescence staining demonstrated that 
BM-MSC expressed high levels of the adhesion molecules JAM-A, CD106, CD44 and 
CD29. A weak positivity was also detected for CD90, while negative for CD54 (Figure 6B). 
 
BM-MSC therapeutic efficacy in DSS-induced acute colitis: action at a distance 
without significant engraftment into the inflamed colon 
To investigate whether MSC had to be injected near the inflamed tissues in order to be 
therapeutically efficient, we administrated 3x106 GFP-MSC subcutaneously (sc) on the 
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dorsal surface of mice after 5 days of DSS treatment; colitic mice injected with saline were 
used as a positive control. MSC administration via sc considerably reduced body weight 
loss of colitic mice (Figure 7A) and significantly improved their DAI (Figure 7B) starting 
from 48 hours after the injection (day 7) compared to positive control mice. At day 10 mice 
were sacrificed and MSC-aggregates were recovered from the subcutaneous cavity of MSC 
treated mice. FACS analysis revealed that their cellular composition was similar to that of 
MSC-aggregates recovered from the peritoneum, with 68% of GFP positive cells (Figure 
7C). Representative hematoxylin eosin staining of these aggregates was reported in Figure 
7D. 
 
The treatment with encapsulated BM-MSC ameliorated DSS-induced colitis 
improving clinical parameters 
To finally corroborate that MSC therapeutic efficacy was completely independent from their 
homing capability to the inflamed gut, we encapsulated MSC into microcapsules of barium 
alginate and evaluated their effectiveness compared to free MSC injection in the treatment 
of DSS-induced acute colitis. 3x106 of either encapsulated or free MSC were implanted into 
the peritoneum of colitic mice 5 days after the beginning of DSS-treatment; colitic mice 
implanted with empty microcapsules were used as a positive control.  
An electron microscope image of encapsulated MSC was reported in Figure 7E. Before 
implantation, viability of cells entrapped within the capsules was assessed by fluorescein 
diacetate and ethidium bromide staining (Figure 7F) that marks in green viable cells and in 
red  those dead. Encapsulated cells maintained their viability until day 10, when mice were 
sacrificed and microcapsules were recovered from their peritoneum (Figure 7G). Both 
encapsulated and free MSC promoted survival of colitic mice (Figure 7H), reduced their 
body weight loss (Figure 7I), DAI (figure 7J), and colon shortening (Figure 7K) compared 
to positive control mice. Interestingly, comparable clinical effects have been observed 
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between the group of mice treated with encapsulated MSC and that of mice receiving free 
MSC. 
 
BM-MSC expressed and secreted high levels of TNF-α stimulated gene/protein 6 in 
vitro 
The efficacy of MSC treatment in our experimental model of colitis appeared completely 
independent from their homing capability to the site of inflammation. Therefore, one or 
more soluble factors produced and secreted by MSC were hypothesized to be responsible 
for their effectiveness. Thus, we tested MSC for the expression levels of many genes, which 
were known to provide their therapeutic efficacy in pathologies other than colitis [143, 156-
159, 162, 164, 167-169]. We discovered that our MSC at  baseline without any stimulation 
expressed high transcript levels of TNF-α stimulated gene/protein 6 (TSG-6) (Figure 8A), 
which is  a ~35 kDa secreted protein known to be involved in cell migration and 
extracellular matrix stability and remodelling by enhancing the serine protease inhibitory 
activity of inter-alpha-inhibitor [203]. TSG-6 protein expression was also confirmed by 
immunofluorescence and western blot analysis as reported in Figure 8B. 
Furthermore, ELISA assay, performed on supernatant collected from MSC culture, 
demonstrated that MSC were able not only to synthesized TSG-6, but also to secrete the 
protein in their surrounding environment (Figure 8B). 
 
Treatment with MSC increased serum levels of TSG-6 
Serum samples of colitic mice treated either with MSC or saline were collected 48 and 72 
hours after injection and were analyzed for the presence of TSG-6 by ELISA. We found an 
increase of TSG-6 in MSC treated mice serum compared with untreated colitic mice at 48 
hours, which became significant at 72 hours (Figure 8C). 
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MSC-aggregates released in ex vivo high amounts of TSG-6 
Although we do not have any direct evidence of the source of TSG-6, we suppose that MSC 
once implanted release TSG-6 in vivo. To test in part this hypothesis, MSC-aggregates were 
recovered from the peritoneal cavity of colitic mice and either stained for TSG-6 directly or 
put in culture to evaluate secreted TSG-6 levels in their supernatant. Whole mount staining 
of MSC-aggregates revealed a strong positivity for TSG-6, in particular in the internal core 
of these aggregates as shown in the Z-stack images of MSC-aggregates (Figure 8D-E). 
Furthermore, ELISA assay performed on organ culture supernatants of MSC-aggregates 
collected 48 and 72 hours after MSC injection, showed a high secretion of TSG-6 at 48 
hours, which was partially maintained at 72 hours (Figure 8F). 
 
Exogenous TSG-6 administration ameliorated DSS-induced colitis improving clinical 
parameters  
In order to test whether TSG-6 could be considered one of the responsible soluble factors of 
the beneficial effects of MSC in the treatement of DSS-induced acute colitis, recombinant 
murine TSG-6 (rmTSG-6) was delivered intraperitoneally to colitic mice and its therapeutic 
efficacy was compared to that of MSC administration. After several experiments for setting 
the timeline and the right dose of TSG-6, colitic mice were injected daily with 4 µg rmTSG-
6 intraperitoneally starting from day 5 of DSS treatment until day 9, while MSC were 
administered as a single intraperitoneal dose of 3x106 cells at day 5. Colitic mice injected 
with saline represented positive control. Although both TSG-6 and MSC administration 
considerably improved survival of colitic mice (Figure 9A), reduced their body weight loss 
(Figure 9B) and ameliorated their DAI (Figure 9C) compared to positive control mice, mice 
injected with rmTSG-6 displayed a much less severe clinical profile. Furthermore, after 10 
days of DSS treatment, positive control mice appeared physically exhausted, due to 
systemic inflammation derived from severe colon damage caused by DSS treatment (Figure 
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9D). On the contrary, colitic mice injected with rmTSG-6 appeared healthy and vital (Figure 
9D). We therefore hypothesized that TSG-6 not only locally reduced colon inflammation, 
but avoided its propagation into the entire organism. At day 10 colonscopic analysis of all 
groups was performed. In line with clinical parameters, colons of TSG-6 treated mice 
displayed less mucosal hyperemia, thickening and ulcerations compared to colons of 
positive control mice; group of mice injected with MSC showed an intermediate level of 
inflammation (Figure 9E). Furthermore, mice treated with both TSG-6 and MSC displayed 
lower histological score together with less infiltrating inflammatory cells compared to 
positive control mice (Figure 9E). Representative colonoscopy and histological images were 
shown in Figure 9E. Taken together these results clearly demonstrated that rmTSG-6 
administration was strongly effective in the treatment of DSS-induced acute colitis and in 
the attenuation of systemic effects produced by exacerbated colonic damage. 
 
rmTSG-6 administration reduced the inflammatory immune response in mice with 
DSS-induced colitis 
Pro-inflammatory cytokine and chemokine levels were evaluated in serum, colon and 
mesenteric lymph nodes of colitic mice treated with either rmTSG-6 or saline after 10 days 
of DSS treatment. As reported in Figure 10, TSG-6 injections reduced markedly the serum 
levels of  pro-inflammatory cytokines of Th1 and Th2 pathways such as IL-6, IFN-y, IL-5 
and  IL-13, and chemokine MCP-1. No significant differences were detected between TSG-
6 and saline-treated mice for IL-12p40, IL-12p70, IL-4, IL-17a, TNF-α and KC levels. 
Interestingly, the treatment with TSG-6 demonstrated different patterns of serum cytokine 
expression compared to MSC-treated mice. Indeed, MSC-treated mice had lower serum 
levels of TNF-α, IL-17a and KC and significantly higher levels of IL-10 than TSG-6 treated 
mice (Figure 10). 
Anti-inflammatory and pro-inflammatory cytokine patterns were analyzed in colonic 
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mucosa and mesenteric lymph nodes of all groups by RT qPCR.  
Although no significant differences were found between treated and untreated-mice, the 
groups treated with TSG-6 and MSC displayed a trend of reduction in typically Th1 
cytokine IL-6 and an increase in Th2 cytokines such as IL-5 and IL-13 compared to saline 
treated-mice in the colon (Figure 11), while no changes were observed in the mesenteric 
lymph nodes except for TGF-β level which was significantly higher in MSC treated mice 
compared to TSG-6 and saline injected mice (Figure 12). 
Furthermore, both TSG-6 and MSC administration reduced transcript levels of the two 
chemokines MCP-1 and MIP-1α in the colon of colitic mice compared to untreated mice. 
However, while MSC treatment only produced a trend of reduction in the transcript levels 
of these two pro-inflammatory chemokines, TSG-6 induced statistically significant effect in 
reducing MCP-1 and MIP-1α levels as well as in the serum (Figure 11).  
In line with reduced levels of pro-inflammatory cytokines, TSG-6 and MSC treated mice 
showed lower percentage of CD45 positive leukocytes infiltrating colonic mucosa compared 
to untreated mice (Figure 13A). Interestingly, TSG-6 administration displayed a trend of 
reduction in the percentage of  polymorphonuclear leukocytes (PMN) evaluated as 
percentage of Ly6G positive cells gated on CD45 positive cells, and a trend of increase in 
the percentage of T regulatory cells  (Treg) evaluated as percentage of CD4 positive 
CD25positive FoxP3 bright regulatory T cells infiltrating the mucosa. In addition, TSG-6 
administration also produced an increase in the percentage of colonic macrophages 
evaluated as percentage of F4/80 positive cells gated on CD45 positive cells, which was 
significantly higher compared to saline and MSC-treated mice (Figure 13A). 
 
rmTSG-6 decreased pro-inflammatory proteases in mice with DSS-induced colitis 
Emerging studies have been shown that in many experimental models of human pathologies 
the anti-inflammatory properties of TSG-6 were due at least in part to its capability to 
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enhance the serine protease inhibitory activity of inter-alpha-inhibitor (IαI), blocking the 
subsequent activation of  matrix metalloproteinases (MMPs) [156, 164, 167]. To test 
whether the protective effects mediated by TSG-6 or MSC treatment inhibited mucosal 
MMP-activation, the expression of MMP-3, MMP-9 and MMP-12, which are overexpressed 
in the inflamed mucosa of IBD patients, was analyzed. Transcript MMP levels showed a 
significant decrease of MMP3 and MMP9 specifically in colons of TSG-6 and MSC 
injected mice compared to untreated mice (Figure 13B), while no statistically difference 
was detected between all groups for MMP12. In order to confirm the results obtained by 
RT-PCR on protein level, proteins were isolated from the same tissue samples. Using 
specific antibodies against MMP3 and 9 a distinction between the latent pro-form and the 
active form of the MMPs was possible. Results of western blots reported in Figure 13C 
demonstrated a marked reduction in MMP3 and MMP9 active form in treated mice, which 
is strong in TSG-6 and only moderate in MSC injected-mice. These results indicated that 
MMP3 and MMP9 activities are modulated by both TSG-6 and MSC treatment. 
52 
 
IV. FIGURES  
FIGURE 1. 
 
Figure 1. Purification and characterization of BM- and A-MSC phenotype. 
(A) According to their cell surface marker expression (Lineage-, CD31- and Sca-1+, left panel), 
BM-MSC were FACS-sorted from a mixed bone marrow cell culture, and their percentage (0,6%) is 
reported. Sorted BM-MSC were then expanded and phenotypically characterized by FACS for the 
presence and the absence of MSC surface markers and the percentage of positivity for each marker 
is reported (right panel). (B) The same protocol was used to isolate A-MSC from subcutaneous 
abdominal fat, and the percentage of A-MSC obtained is reported (left panel). A-MSC were also 
phenotypically characterized and the percentage of positivity for each surface marker is reported 
(right panel). (C) Representative confocal images of BM- and A-MSC before (left panel) and after 
differentiation into osteoblasts (central panel, bright field images) and adipocytes (right panel, 
confocal images). Lipid vacuoles accumulation (red) is typical of differentiated adipocytes (right 
panel), while extracellular calcium deposition (black, central panel) is typical of differentiated 
osteoblasts. Nuclei were counterstained with either hematoxylin (light blue, central panel) or DAPI 
(blue, right panel), respectively. 
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FIGURE 2. 
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Figure 2. Comparison of BM- and A-MSC therapeutic efficacy in the DSS experimental model 
of acute colitis. 
 
Colitic mice in a C57BL/6N genetic background, were ip injected with 3x106 of either BM- or A-
MSC. Healthy mice receiving BM- or A-MSC and colitic mice injected only with saline were used 
as negative and positive controls, respectively. Body weight loss (A) and disease activity index 
(DAI) (B) were monitored daily during the entire experiment. After 10 days of DSS treatment, mice 
were sacrificed, and colons were extracted for length measurements (C) and histological analysis 
(D). In D histological data are reported as inflammatory scores and grade of inflamed tissue involved 
(upper panel), while representative Hematoxylin and Eosin (H&E) images of inflamed colon 10 days 
after DSS treatment, are reported the lower panel. (E) Part of the extracted colons were 
homogenized in lysis buffer and analyzed for cytokine and chemokine expression, by ELISA. 
Chemokine and cytokine concentrations were normalized per mg of tissue. Values are expressed as 
mean ± SEM; n=4 mice for DSS groups; n=3 for healthy groups. *P< 0.05; **P<0.01; ***P<0.001. 
 
 
 
 
 
FIGURE 3. 
	  
Figure 3. In vitro BM- and A-MSC immunomodulatory properties 
Proliferation of CD3ε/CD28-activated splenocytes (SPL) co-cultured with BM-MSC (left panel) and 
A-MSC (right panel) at different ratio (SPL:MSC, 2.5:1; 5:1; 10:1 and 50:1) (grey bars) was 
evaluated. Naïve SPL (white bars) and  CD3ε/CD28-activated SPL alone (black bars) were used as 
negative and positive control, respectively. Results were expressed as percentage of SPL 
proliferation. Values are expressed as mean ± SEM; n=3 wells for each group.*** P<0.001.	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FIGURE 4. 
	  
Figure 4: Capability of intraperitoneally delivered BM-MSC to engraft into inflamed colon 
Healthy and colitic mice were ip injected with 3x106 GFP-MSC at day 5 of DSS treatment and 
colons were collected 24, 48, 96 and 120 hours after the injection to visualize GFP+ cells by FACS. 
Colitic mice ip injected with saline were used as negative control. (A) Representative Dot Plots at 48 
hours after the injection (left panel) and GFP+ MSC frequency expressed as percentage in healthy 
and colitic colons at all time points (right panel) are reported. All frequencies are referred to viable 
cells. (B,C) After 10 days of DSS treatment, GFP+ MSC were visualized by immunohistochemistry 
on paraffin-embedded sections of colitic mice. Nuclei were conterstained with hematoxylin (light 
blue). Representative images of GFP+ cells engrafted into epithelium (B) and endothelium (C) are 
shown.  
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FIGURE	  5.	  
	  
Fig. 5: Intraperitoneally delivered BM-MSC remained in the peritoneal cavity forming  
cellular aggregates 
MSC (3x106) pre-stained with DilC18 (3) were injected in colitic mice and 24, 48 and 72 hours later 
colons were extracted and stained for CD31, by Whole Mount technique.  (A) Representative image 
of MSC (red) aggregating outside the bowel wall vessels (green) 72 hours after the injection is 
reported. (B) After 10 days of DSS treatment, both healthy and colitic mice injected with 3x106 
GFP-MSC at day 5 were sacrificed and  peritoneal lavages were performed. Representative phase-
contrast image of structures recovered from the peritoneal cavity is shown. (C) Recovered structures 
were either fixed in PFA 4% and whole mount stained for CD3 (T lymphocytes; red signal) and 
CD68 (macrophages; grey signal). (D) Recovered structures were digested and analyzed by flow 
cytometry. CD45+ cells (leukocytes) were double-stained for CD11b and F4/80 (macrophages), 
CD11b and Ly6G (PMN), CD3 (T lymphocytes) and B220 (B lymphocytes). Representative Dot 
Plot of  CD45+/CD11b+ cells stained for F4/80 or Ly6G, and  representative Dot Plot of CD45+ 
Side Scatter (SSC) low cells stained for CD3 and B220 are shown. All cell frequencies were referred 
to CD45+ cells, while the frequency of GFP-MSC was referred to total viable cells. (E) Viability of 
cells within the structures was assessed by fluorescein diacetate and ethidium bromide staining; 
green signal represented viable cells, while red signal represented dead ones. (F) Recovered 
structures were also collected and cultured. After 3 days in culture many cells detached from the 
structures,  adhering to the plate. Representative phase-contrast image of a cultured structure, with 
detached cells. (G) The phenotype of cells detaching from the cultured structures was analyze by 
FACS for Lineage-, CD31-, CD45- and GFP+ (G) and relative Dot Plots are reported. (H,I) 
Deposition of collagen into the structures was analyzed by both two photon microscopy and  Picro-
Sirius Red staining. Representative two photon microscopy image of second harmonic generation 
signal derived from collagen fibers (H) and representative bright field image of Picro-Sirius Red 
staining (I, collagen in red) are reported.  
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FIGURE 6. 
	  
Figure 6: BM-MSC expression levels of chemokine receptors and cell adhesion molecules 
(CAMs) 
(A) The expression profile of chemokine receptors was analyzed in PEC macropheges (positive 
control) and MSC,  by real-time qPCR. Results are expressed as mRNA levels relative to GAPDH 
expression levels. (B) Expression levels of CAMs and surface molecules involved in the interaction 
between cells and activated endothelium and/or extracellular matrix were quantified by flow 
cytometry (left panel) and/or immunofluorescence (right panel). Percentage of positive cells  for 
each molecule is reported. In immunofluorescence images red signal represents positivity for CAM, 
while nuclei were counterstained with DAPI (blue).  
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FIGURE 7. 
	  
	  
Figure 7: BM-MSC capability to exert therapeutic efficacy at distance in the DSS  
experimental model of acute colitis. 
MSC (3x106 ) or saline (positive control) were administered subcutaneously to colitic mice after 5 
days of DSS treatment. Loss of body weight (A) and DAI (B) were monitored daily during the entire 
experiment. (C) At day 10 after DSS treatment mice were sacrificed and structures recovered from 
their subcutaneous cavities and analyzed for GFP expression by FACS. Percentage of GFP+ cells is 
reported. (D) These structures were also paraffin-embedded  and stained for histologic examination. 
(E-G) MSC migration was blocked by encapsulation into barium alginate microcapsules. An 
electron microscopy image of encapsulated cells is shown (E). Fluorescein diacetate and ethidium 
bromide staining was employed to verify the viability of cells entrapped within the capsules both 
before implantation (F) and after 5 days into the peritoneal cavity (G).  (H-K) 3x106  of MSC either 
encapsulated or not were implanted into the peritoneal cavity of colitic mice 5 days after the DSS 
treatment. Colitic mice implanted with empty capsules were used as positive control. Survival (H), 
loss of body weight (I) and DAI (J) were monitored daily during the entire experiment, while colon 
length was measured at the end of the experiment, when mice were sacrificed (K). Values are mean 
± SEM; n=5 mice for all groups. *P< 0.05; **P<0.01.	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FIGURE 8 
	  
	  
Figure 8: TNF-α-stimulated gene/protein 6 (TSG-6) production and secretion by BM-
MSC in vitro, in vivo, and ex vivo 
(A) MSC were analyzed for transcript expression levels of anti-inflammatory factors known 
to be responsible for their therapeutic efficacy in many pathologies other than colitis, by RT 
qPCR. (B) Among all factors analyzed, MSC expression levels of TSG-6 protein was 
investigated by both immunofluorescence (upper panel) and western blot (lower panel). Red 
signal represented positivity for TSG-6 signal, while nuclei were counterstained with DAPI 
(blue); recombinant murine TSG-6 was used as positive control in western blot. Levels of 
secreted TSG-6 on supernatants collected from MSC culture, were quantified by ELISA and 
expressed as pg/ml. (C) GFP-MSC (3x106 ) or saline were ip injected into colitic mice 5 
days after DSS treatment, while naïve mice were employed as control. Serum levels were 
then collected 48 and 72 hours after the injection and analyzed for TSG-6 levels by ELISA. 
(D,E) Ten days after DSS treatment, mice were sacrificed, structures were recovered from 
their peritoneum and whole mount stained for TSG-6 (red). GFP-MSC are visualized in 
green. (F) Structures isolated from the peritoneum of colitic mice at 48 and 72 hours after 
GFP-MSC injection were cultured for 24 hours and their supernatants were analyzed for 
TSG-6 secretion levels, by ELISA. Values are expressed as mean ± SEM; n=5 mice for all 
groups. *P< 0.05. 
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FIGURE 9 
	  
	  
	  
Figure 9: Therapeutic efficacy of recombinant murine TSG-6 (rmTSG-6) administered 
via ip in the treatment of DSS-induced acute colitis 
Colitis was induced in C57BL/6N mice by administration of 3% DSS in drinking water ad 
libitum for 10 days. Mice were divided into 3 groups. In the first group colitic mice received 
3x106 MSC intraperitoneally 5 days after DSS treatment; in the second group colitic mice 
were administered daily with rmTSG-6 (4µg/mouse) starting from day 5 until day 9 after 
DSS treatment.  Positive control group was represented by colitic mice receiving saline. 
Survival (A), loss of body weight (B) and DAI (C) were monitored daily during the entire 
experiment. (D) Pictures of mice injected with either saline (upper panel) or rmTSG-6 
(lower panel) are reported to show their different physical condition after 10 days of DSS 
treatment. (E) Before sacrifice, colonscopic analysis was performed for each group, while 
after sacrifice colons were formalin-fixed and paraffin-embedded for histologic 
examination. Representative endoscopical (upper panel) and histological (lower panel) 
images together with the histological score (right panel) are shown  Values are expressed as 
mean ± SEM; n=5 mice for all groups. *P< 0.05; **P<0.01; ***P<0.001. 
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FIGURE 10 
	  
	  
	  
Figure 10: Systemic effect of rmTSG-6 treatment on chemokine and cytokine serum 
levels. 
Serum samples from colitic mice intraperitoneally injected with either MSC (3x106) or 
rmTSG-6 were collected after 10 days of DSS treatment and analyzed for IL-6, IFN-γ, IL-
12p40, IL-12p70, IL-4, IL-5, IL-13, IL-17a, TNF-α, IL-10 cytokine levels and KC, MCP-1 
chemokine levels by Bio-Plex assay. Positive and negative controls were represented by 
colitic mice injected with saline and healthy mice, respectively. Values are expressed as 
mean ± SEM; n=5 mice for all groups. *P< 0.05; **P<0.01. 
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FIGURE 11 
	  
	  
Figure 11: Analysis of cytokine/chemokine expression profile in colon of rmTSG-6-
treated mice 
Colitic mice were intraperitoneally injected with either MSC (3x106) or rmTSG-6 and  after 
10 days of DSS treatment colons were collected. Positive and negative controls were 
represented by colons recovered from colitic mice injected with saline and from healthy 
mice, respectively. After RNA extraction and  retrotranscription, expression of anti-
inflammatory cytokine TGF-β and IL-10 together with pro-inflammatory cytokine IFN-γ, 
IL-6, IL-4, IL-5, IL-13, IL-17a as well as chemokines MCP-1 and MIP-1α was determined 
by RT-qPCR. For each molecule, results are expressed as relative mRNA expression levels 
over the total amount of GAPDH or Actin.  Values are mean ± SEM; n=5 mice for all 
groups. *P< 0.05 
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FIGURE 12 
	  
	  
Figure 12: Analysis of cytokine expression profile in MLNs of rmTSG-6 treated mice 
Colitic mice were intraperitoneally injected with either MSC (3x106) or rmTSG-6 and  after 
10 days of DSS treatment MLNs were collected. Positive and negative controls were 
represented by MLNs recovered from colitic mice injected with saline and from healthy 
mice, respectively. After RNA extraction and  retrotranscription, expression of anti-
inflammatory cytokine TGF-β and IL-10 together with pro-inflammatory cytokine IFN-γ, 
IL-6, IL-4, IL-5, IL-13, IL-17a was determined by RT-qPCR. For each molecule, results are 
expressed as relative mRNA expression levels over the total amount of GAPDH.  Values 
are mean ± SEM; n=5 mice for all groups. *P< 0.05 
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FIGURE 13 
	  
	  
Figure 13: Analysis of inflammatory cells and matrix metalloproteinases (MMPs) 
expression in colons of colitic mice treated with rmTSG-6  
Colitic mice were intraperitoneally injected with either MSC (3x106) or rmTSG-6 and  after 
10 days of DSS treatment colons were collected. Positive and negative controls were 
represented by colons recovered from colitic mice injected with saline and from healthy 
mice, respectively. (A) After digestion, colons were analyzed for the presence of infiltrating 
inflammatory cells (CD45+), polymorphonuclear cells (PMN), regulatory Tcells (Treg) and 
macrophages, by FACS. Frequency of CD45+ cells was referred to total viable cells, while 
all the other percentages were referred to CD45+ cells. (B,C) From the same colons RNA 
and proteins were simultaneously extracted and expression levels of matrix 
metalloproteinases MMP3, MMP9 and MMP12 were determined by both RT qPCR (B) and 
western blot (C). Actin was used as loading control for protein expression levels. RT-qPCR 
results are expressed as relative mRNA expression levels over the total amount of GAPDH 
or Actin.  Values are mean ± SEM; n=5 mice for all groups. *P< 0.05. 
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V. DISCUSSION 
Cellular therapy with mesenchymal stem cells is a promising new approach capable of 
addressing yet unmet medical needs for the treatment of inflammatory bowel diseases, 
which are characterized by sterile inflammation leading to loss of intestinal function [1]. 
The considerable excitement surrounding the  MSC field was initially based on the unique 
biological properties of these cells and their capacity to self-renew and regenerate tissue and 
organ systems [84-86]; later, the immunomodulatory ability of stem cell therapy has 
become also apparent. Indeed, they were also demonstrated to be tolerogenic, and to 
modulate the immune system, dampening the inflammation and restoring the balance 
between regulatory and effector T cell response [122]. Results from murine models of 
colitis and ongoing clinical trials are encouraging, suggesting that MSC therapy is safe and 
effective in ameliorating experimental colitis and promoting clinical remission in most 
treated patients [81, 171]. However, the mechanism(s) through which these cells exert 
therapeutic efficacy in the intestine remain unclear, basic science and animal experiments 
continue to play an important role in the understanding of the mechanisms involved. 
Mesenchymal stem cells coexist with other cell types depending on source. In the bone 
marrow they coexist with hematopoietic stem cells and their frequency is very low (1 MSC 
every 100000/1000000 bone marrow cells) [82, 83]. Since the low frequency and the 
absence of specific markers for their characterization, the first critical and important step in 
the study of MSC activities is represented by their purity. Most of isolation protocols are 
based on MSC property to adhere to plastic once put in culture [118], but these methods 
lead to the obtainment a MSC population contaminated. In order to shed light on the 
mechanisms underlying the beneficial effects of MSC in the IBD, I  set up in the first part of 
my study a new isolation protocol to obtain a pure population of MSC. This new 
purification method took advantage of negative selection for endothelial and hematopoietic 
markers such as CD31 and  Lineage, and positive selection for Sca-1, marker with high 
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grade of stemness. The double selection permitted to obtain high purity of MSC population 
without affecting their properties, as demonstrated by our results. MSC can be isolated from 
different adult tissues such as bone marrow, cartilage, muscle, tendon and fat. In order to 
investigate the mechanisms of MSC-based therapy for IBD, it is necessary to identify the 
best cell source in terms of frequency of cells, low risks for the patients and cell activity. 
Although bone marrow remains the main source of MSC for clinical studies, adipose tissue 
is considered an ideal source due to accessibility. Therefore I decided to compare in terms 
of phenotype, properties and therapeutic efficacy MSC isolated from both bone marrow 
(BM) and adipose tissue (A). Importantly, mice of 4 to 6 week-old were used, as MSC 
frequency was demonstrated to inversely correlate with the age of mice [204]. Surprisingly, 
the frequency of sorted MSC cells was completely different depending on tissue source, 
going from 0.6% in the bone marrow to 96.7% in the adipose tissue. Analysing the quality 
of cultures generated by both sorted cells, I found that they consisted of pure populations of 
MSC, as demonstrated by the pattern of surface markers expressed by them. Interestingly, 
BM- and A-MSC displayed similar phenotype, differing only for the expression level of 
CD90, which was almost absent on BM-MSC surface, while strongly expressed by A-MSC. 
CD90, also known as Thy-1, is commonly used as a marker for a variety of stem cells and 
for the axonal processes of mature neurons. The function of CD90 has not yet been fully 
elucidated. It seems to play role in cell-cell and cell-matrix interactions, and to be 
implicated in neurite outgrowth, nerve regeneration, apoptosis, metastasis, inflammation 
and fibrosis [205]. Its specific function on MSC surface remains unknown. Importantly, it 
was demonstrated that while CD90 expression level is high on human MSC surface, it can 
vary on murine MSC, depending also on the strain of mice from which they are isolated as 
well as on the tissue source [119]. Notably, when administered to colitic mice at day 5 of 
DSS treatment, BM-MSC appeared much more effective than A-MSC in ameliorating both 
their clinical and histological scores, and in reducing the amount of pro-inflammatory 
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cytokines and chemokines in the inflamed colon. These in vivo differences between the two 
stem cell lines could be related to different in vitro properties that they exerted. Indeed, 
beside a different morphology, BM- and A-MSC differed for differentiation potential, with 
the latter being much more prone to originate adipocytes than osteoblasts. This could reflect 
a different composition and grade of stemness of the two cultures, with BM-MSC mainly 
constituted by uncommitted “bona fide” stem cells, and A-MSC formed by committed, 
more differentiated progenitors. As a consequence, the regenerative potential of the two 
stem cell lines was expected to be different also in vivo, possibly affecting their therapeutic 
efficacy. A second explanation for BM-MSC being more effective in the treatment of DSS-
induced colitis, could be represented by their capability to strongly inhibit the proliferation 
of activated splenocytes (SPLs), also if highly diluted. On the contrary, A-MSC were able to 
suppress splenocytes proliferation only in cultures characterized by low A-MSC-SPLs ratio. 
Thus, whether reduced immunomodulatory properties, or regenerative potential, or both 
were the cause of reduced A-MSC therapeutic efficacy compared to BM-MSC in DSS 
model of colitis, remains to be clarified. These data demonstrate that MSC cultures 
established from different tissue sources are not equal in terms of both in vitro and in vivo 
properties, and could therefore display different effects once translated to the clinical 
practice. Given that BM-MSC display a higher efficacy in ameliorating intestinal 
inflammation than A-MSC, the second part of my thesis has been focused on investigating 
the fundamental mechanisms by which BM-MSC exerted therapeutic efficacy in 
experimental model of colitis. There are several experimental models of colitis which 
provide different conditions for the study of factors involved in the pathogenesis of 
inflammatory bowel diseases such as: environmental factors, the role of specific immune 
and genetic factors, and therapeutic options in IBD. For the aims of this thesis I used the 
DSS model of colitis that is the most common, quick and easily reproducible chemically 
induced colitis model. It has similarities to clinical and histological features of human IBD 
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with UC characteristics [65].  
Data coming from experimental models suggest the existence of two alternative 
mechanisms explaining the beneficial effects of MSC. The first mechanism proposed that 
after systemic delivery, MSC migrated to the site of inflammation where they both 
differentiated into injured cells and locally modulated the inflammatory response [155, 
166]. Alternatively, MSC were identified as a natural source of trophic and anti-
inflammatory factors, which they produced at distance upon stimulation, without engrafting 
into tissue [206]. In order to address which of them proposed mechanisms were involved in 
intestinal diseases,  BM-MSC from GFP mice were intraperitoneally injected, and their 
presence in the colon and MLNs was evaluated at different time points using different 
approaches.  
Surprisingly, we found that MSC did not successfully engraft either MLNs or colon at any 
time points tested, with a frequency of less than 1% in the latter 48h after the injection. 
Other organs, such as liver, spleen and lungs were therefore investigated at different time 
points for MSC presence, but no GFP+ cells were detected. The work hypothesis was that 
MSC after intraperitoneal injection entered the lymphatic and/or blood circulation, migrated 
throughout the body and homed to inflamed gut via activation of specific 
chemokines/chemokine receptors axis. In order to verify whether the absence of MSC in the 
peritoneal organs was due to a defective expression of chemokine receptors and/or adhesion 
molecules in these cells, we analyzed the expression of a panel of chemokines/chemokine 
receptors and integrins/adhesion molecules could be involved in the migratory activity of 
MSC to the gut. Interestingly, BM-MSC expressed very low levels of chemokine receptors 
particularly of those involved in migration towards intestine (CCR9) and secondary 
lymphoid organs, such as MLNs (CCR7), but were strongly positive for most of the 
integrins and adhesion molecules tested. Therefore, MSC administered via ip not only failed 
to engraft peritoneal organs, but were not able to enter the circulatory system, remaining in 
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the site of injection. Indeed, MSC aggregated outside the bowel wall vessels of the distal 
colon together with immune cells, especially macrophages, T and B lymphocytes and 
polymorphonuclear cells (PMN), generating MSC-aggregated. These structures appeared 
after 48 hours of MSC administration, and increased their size day-by-day, resembling 
lymphoid structures either for shape and size. Importantly, cells contained within the 
structures were vital, as demonstrated not only by fluorescein diacetate and ethidium 
bromide stain, but also by their capability to detach from the structures and adhere to plastic 
once put in culture. In addition, it was found that structures were not simple cell aggregates, 
but organized units, characterized by deposition of an extracellular matrix of collagen, an 
internal MSC core and immune cells on their surface. This organization, together with their 
cellular composition, resemble that of tertiary lymphoid structures (TLS), which are 
inducible non-capsulated lymphoid aggregates, capable of ectopic immunological activity, 
that usually originate in inflamed tissues as a result of immune infiltration [207]. 
Development of TLS was well characterized in the synovium of rheumatoid arthritis 
patients, where the initial recruitment of lymphocytes displays a disorganized accumulation 
of T and B cells around a central blood vessel. The increasing size of the aggregate is 
accompanied by variable upregulation of key molecules regulating lymphoid organogenesis 
and homeostasis in physiological conditions, such as LTβ and lymphoid chemokines 
CXCL13, CCL21 and CCL19. Expression of these chemokines leads to initial T/B cells 
compartmentalization, and to increased accumulation of LTβ+ hematopoietic cells 
promoting further differentiation/proliferation of stromal and vascular cells. Amplification 
of these processes leads to the formation of functional germinal centre (GC) inside these 
structures, where differentiated follicular dendritic cells (FDC) accumulate and give rise to a 
network which support expression of activation-induced cytidine deaminase (AID) in B 
lymphocytes. In this environment B cells undergo Ig repertoire diversification and affinity 
maturation, suggesting that these lymphoid aggregates may function as “protective niches” 
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for local B cell differentiation and auto-antibody production, with the potential of directly 
contributing to the immune response. However, it is still debated whether they directly 
support local pro-inflammatory activity by facilitating cell cooperation or play a regulatory, 
counter-inflammatory role, since evidences supporting both theses exist. Recently, it has 
been proposed that formation of ectopic lymphoid aggregates in an inflamed tissue is not 
necessarily detrimental or beneficial per se, but their specific physiopathological effect 
might be dynamically or spatially dependent on their functional status and the 
characteristics of the surrounding environment [207]. Thus, further investigations are 
necessary to assess whether structures identified in the peritoneal cavity of mice injected 
with MSC are bona fide TLS or not. The solid evidence is that MSC administration is 
effective in ameliorating DSS-induced colitis, probably via secretion of soluble factor(s), 
but we still have to verify whether MSC organization into structures together with immune 
cells is necessary for their therapeutic efficacy. In this regard, it was recently demonstrated 
that MSC cultured as 3D aggregates or as spheroids were self-activated to express anti-
inflammatory proteins and appeared more effective than MSC from adherent monolayer 
cultures in suppressing inflammatory responses both in vitro and in vivo [177]. Thus, 
considering that MSC are supposed to exist in adult tissue organized into niche [117], we 
can speculate that, alternatively to TLS, MSC aggregates could represent a reproduction of 
their original niche, which MSC reconstitute once injected in order to reproduce their 
natural environment, where their beneficial effects are maximized. Surprisingly, structures 
were found not only in the peritoneum of colitic mice, but also in that of healthy mice 
administered with MSC, suggesting that these cells are able to aggregate and recruit 
immune cells per se, independently from the presence of an inflammatory environment 
surrounding them. As a consequence, it might be hypothesized that the generation of 
organized structures prompt by MSC do not need their previous activation by 
proinflammatory cytokines, but happens spontaneously after their injection. This could be 
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probably due to in vitro MSC handling before injection, which might promote and maintain 
these cells in a constant activation state. Indeed, in order to increase MSC number, they are 
cultured in specific media rich of factors that stimulate cells proliferation and block their 
differentiation. Beside these effects, it is possible that the same factors induce a constitutive 
activation in MSC. Recently, it has been demonstrated that in experimental autoimmune 
encephalomyelitis MSC aggregate with immune cells in vivo[153]. The authors of this study 
have reported that intracerebroventricular (ICV)-transplanted MSC migrated into the brain 
parenchyma and, together with T and B cells, formed cellular masses. However, these 
masses appear different from MSC-aggregates that I observe in the peritoneal cavity. 
Indeed, they were observed only when locally injected MSC accumulated at high density in 
the brain parenchyma, which depend on the number of ICV-transplanted cells and 
environmental factors, such as the disease activity. In my case accumulation of MSC at high 
density was unlikely, since intraperitoneally administered cells spread throughout the 
peritoneum. In addition, it was reported that the probability to develop masses into the brain 
directly correlated with the severity of the EAE, while I observed structures formation 
independently on the presence of inflammation, both in colitic and healthy mice. Finally, 
MSC entrapped into masses instead of producing therapeutic effects, generated focal 
inflammation, demyelination, axonal loss and increased collagen-fibronectin deposition. 
The final confirmation that MSC therapeutic efficacy occurs via production and secretion of 
soluble factors, without the need of gut homing was obtained by observing that MSC, 
encapsulated into alginate-based microcapsules and implanted into the peritoneum of mice, 
were as effective as free MSC in ameliorating DSS-induced colitis. Importantly, these 
microcapsules entrapped the cells inside but are completely permeable to soluble factors. Of 
note, MSC microcapsules could be approximately considered as small structures, since cells 
are forced to stay in close contact and therefore they can interact each other. This reinforces 
the idea that MSC need to aggregate in order to be able to exert their therapeutic efficacy, as 
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previously discussed. However, it has to be taken into consideration that MSC entrapped 
within microcapsules cannot directly interact with immune cells as happened in the 
structures. This observation gives rise to many doubts regarding the contribution exerted by 
immune cells in the structures, since their absence in MSC microcapsules does not prevent 
MSC therapeutic efficacy. Thus, even if the capability of MSC to exert therapeutic efficacy 
in the treatment of DSS-induced colitis without homing to inflamed intestine has been 
definitively demonstrated, further investigation are necessary to better characterized the 
function of the structures, especially the role of immune cells which take part in their 
formation. 
Therefore, MSC administered intraperitoneally remained in the site of injection, where they 
aggregated with immune cells.  However, even if MSC did not migrate towards inflamed 
gut, they stayed close to the inflamed area, that is in the peritoneum. To exclude the 
possibility that in order to be therapeutic MSC had to be administered closed to the site of 
inflammation, I tested the therapeutic efficacy of MSC subcutaneously injected in the 
treatment of colitis. Surprisingly, subcutaneous injections of MSC back of arms were as 
effective as ip administered MSC in reducing body weight loss of mice and ameliorating 
their DAI. Importantly, the observation that subcutaneously injected MSC aggregated along 
with immune cells generating MSC-aggregates, further reinforce the idea that MSC 
aggregation is a pivotal process for their therapeutic efficacy. 
Thus, MSC therapeutic efficacy in the treatment of DSS-induced colitis is probably related 
to their capability of generating MSC-aggregates, where they may cross-talk each other and 
with immune cells, giving rise to a well-organized microenvironment in which they start 
producing and secreting soluble factor(s). Many soluble factors have been identified as 
responsible for MSC therapeutic effects in pathologies other than colitis, as previously 
discussed, and among them I discovered that my MSC expressed and secreted TSG-6 both 
in vitro and in vivo TSG-6 is a ~35kDa secreted protein composed mainly of contiguous 
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Link and CUB modules [203]. By its Link domain, TSG-6 binds to many components of the 
extracellular matrix (ECM), such as hyaluronan (HA), chondroitin-4-sulphate (C4S) and 
aggrecan. Its CUB module is highly conserved between species and occurs in a wide range 
of proteins involved in fertilization and development, suggesting a role for TSG-6 in these 
processes. Although there is little or no constitutive expression of TSG-6 in unstimulated 
tissues, it is produced by a variety of cells in response to a wide range of pro-inflammatory 
factors, such as TNF-α, IL-1 and LPS, as well as various growth factors, like TGF-β, FGF 
and EGF. Once produced and secreted, TSG-6 has been demonstrated to exert anti-
inflammatory effects. In particular it has been shown that it is implicated in several 
processes, which take place during inflammation, in particular in cell proliferation, and 
leukocytes homing to inflamed tissues. The mechanisms underlying these effects are mostly 
unknown, but they seem to involve TSG-6 capability to interact with either HA or inter-α-
inhibitor (IαI), which is a serine protease inhibitor, or both. Indeed, it was recently 
suggested that TSG-6 might somehow participate in the formation of HA·IαI complexes, 
and thus be important for regulating ECM remodelling and/or assembly. In addition, TSG-6 
non-covalent interaction with IαI enhances the anti-plasmin activity of the latter, causing a 
decrease in the activation of MMP, which normally occurs via pro-MMP cleavage exerted 
by plasmin. This blocks MMP degradation of the ECM, a common denominator of any 
inflammatory process. As a consequence, the capability of leukocytes, especially of 
neutrophils, which are the firsts recruited to inflammatory sites, to infiltrate damaged tissues 
is extremely reduced. Alternatively, TSG-6 might limit the extravasation of leukocytes by 
binding HA, which is overexpressed on the activated vascular endothelium. Indeed, HA 
bound to TSG-6 is no more available for interaction with CD44 on leukocytes, which 
normally mediated their extravasation [203]. As anticipated before, MSC in vitro express 
high transcript and protein levels of TSG-6, and were also able to secrete this protein in 
their supernatant. Surprisingly, MSC did not require to be stimulated by TNF-α or other 
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pro-inflammatory cytokines to express and secrete TSG-6 as normally occurred, but they 
were already activated to produce it at the baseline. This finding further reinforces our 
hypothesis that MSC in vitro culture conditions exert a deep impact on their activation state. 
In particular, as mentioned above, media for MSC culture are rich of factors that beside 
stimulating cells proliferation and blocking their differentiation, might render them 
constantly activated. In vivo, colitic mice administered with MSC displayed an increase in 
TSG-6 serum levels especially 72h after injection compared to saline treated mice and naive 
mice.  The whole mount stain for TSG-6 performed on structures recovered from the 
peritoneal cavity of colitic mice 48 and 72h after GFP-MSC injection, demonstrated that 
MSC produced ex vivo TSG-6 and secreted it in the extracellular space, where it could 
contribute to organize the extracellular matrix. In addition, the organ culture of the same 
structures revealed secreted TSG-6 also in their supernatant, whose levels seem to correlate 
with those present in the serum of MSC treated mice. Indeed, if we assume that TSG-6 
secreted by MSC organized into structures requires more or less 24h to be absorbed and to 
appear in the bloodstream, the high levels of TSG-6 secreted ex vivo by the 48h structures, 
could produce in vivo the observed increase in TSG-6 serum levels 72h after MSC injection. 
However, this represents only an hypothesis, since the ex vivo model of structures’ organ 
culture could not truly reproduce their in vivo behavior, and we cannot be sure that the 
increase in TSG-6 serum levels observed in MSC treated mice is exclusively due to MSC 
contribution, and not to other cells prompt by MSC to secrete TSG-6. In this regard, 
isolation of MSC from mice knock out for this protein could shed light on both the role 
played by these cells in providing the enhancement of TSG-6 serum levels once injected 
into colitic mice, and its relevance in determining MSC therapeutic efficacy in the treatment 
of DSS-induced colitis. However, assuming TSG-6 as the soluble factor secreted by MSC 
responsible for most of their therapeutic effects in the treatment of DSS-induced colitis, the 
trend of TSG-6 secretion by structures observed ex vivo, demonstrated that 48h after 
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injection these cells produced the highest amount of TSG-6, which appeared strongly 
reduced at 72h. This is in line with previous findings, which suggest that MSC effects are 
generated soon after their injection that is within 72h and thereafter come to exhaustion. As 
a consequence, in order to prolong their beneficial effects, especially in long-lasting 
experimental models of human pathologies, multiple administrations seem to be necessary. 
To confirm that TSG-6 is therapeutic in the treatment of DSS-induced colitis, rmTSG-6 was 
administered to colitic mice intraperitoneally, and its effects were compared to those exerted 
by MSC. Data coming from ex vivo organ culture of MSC organized into structures 
suggested that they might in vivo continuously release TSG-6 in the peritoneum. This 
process seemed to occur with high efficiency within few hours from their injection, and 
progressively reduced thereafter. In order to reproduce the kinetic of TSG-6 release by 
MSC, multiple administration of rmTSG-6 were performed. Interestingly, exogenous TSG-6 
strongly promoted survival of colitic mice, reduced their body weight loss and ameliorated 
their DAI. Surprisingly, after 10 days of DSS treatment, TSG-6 injected mice appeared 
healthy and vital and displayed reduced colon inflammation compared to saline injected 
mice, as demonstrated by endoscopic and histological analysis. In this study we 
demonstrated that the impressive clinical amelioration of colitis produced by TSG-6 was 
related to its capability to locally reduce colon inflammation, avoiding its propagation into 
the entire organism. Indeed, TSG-6 treated mice displayed reduced levels of both total and 
active MMP3 and MMP9 in the inflamed colon, which in turn decreased the ECM 
degradation and the subsequent leukocytes infiltration. Notably, among leukocytes 
infiltrating inflamed gut, PMN exert detrimental effects, since they are recruited in the early 
phase of colon damaged and promote both the perpetuation and the propagation of the 
inflammatory process [208]. Treatment with rmTSG-6 was demonstrated to specifically 
reduce the percentage of PMN infiltrating the inflamed colon, which resulted in the 
reduction of colon inflammation, as demonstrated by the reduced levels of local pro-
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inflammatory cytokines (especially IL-6) and chemokines (MCP-1 and MIP-1α). 
 
In CONCLUSION, MSC-based therapy is a promising new approach for the treatment of 
IBD.  The results of my thesis demonstrate that the isolation source, procedure, culture 
manipulation as well as species from which MSC are purified could also play an important 
role in the therapeutic efficacy of these cells. Furthermore these data show that once 
injected, at least in DSS experimental model of colitis, MSC do not engraft the inflamed 
colon, but remain in the site of injection where aggregate with immune cells. Overall, my 
study indicates that MSCs do not need to reach the inflamed colon for exerting 
immunomodulatory effects, but dampen the mucosal inflammatory response at distance by 
releasing a soluble factor as potent anti-inflammatory protein TSG-6. 
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VI. METHODS 
Isolation of murine BM-MSC and A-MSC  
BM- and A-MSC were isolated from both C57BL/6 mice and C57BL/6-Tg(UBC-
GFP)30Scha/J mice of (Charles River). BM-MSC were isolated by flushing femurs and 
tibias of mice. The cells obtained were plated at the concentration of 1x106cells/cm2 in 
complete MSC expansion medium (StemCell Technology). A-MSC were isolated from 
abdominal subcutaneous fat of mice by digestion with 1mg/ml Collagenase type I 
(Worthington) for 45 min at 37°C. Cells were then filtered and centrifuged before growing 
in MSC expansion medium. Non-adherent cells were removed from BM-MSC culture 72h 
after plating, while from A-MSC culture after 24h. At passage 3 both BM- and A-MSC 
were sorted with FACSAria II flow cytometer (BD Biosciences) selecting Lineage Cell 
Detection Cocktail-, CD31- and Sca-1+ cells. 
 
Morphologic characterization and differentiation potential of murine BM- and A-
MSC 
BM- and A-MSC were seeded on PolyLysine (1:10 in PBS; Sigma-Aldrich) on glass 
coverslips (13mm diameter; Carolina Biological Supply), which were either fixed with pre-
warmed paraformaldehyde (PFA) 2% for 10 min at 37°C to analyse their morphology or 
cultured with specific differentiation media to differentiate cells into osteoblasts and 
adipocytes. Osteoblastic differentiation was achieved by culturing both cell lines in 
complete DMEM supplemented with indomethacin 0.14mM (SIGMA), ascorbic acid 
0.284mM (SIGMA) and dexamethasone 1x10-4mM (MP Biomedicals), while adipogenic 
differentiation was obtained by using complete DMEM supplemented with glycerol 
phosphate 10mM (SIGMA), dexamethasone 1x10-4mM and ascorbic acid 0.284mM. After 3 
weeks differentiated adipocytes were checked by lipid vacuoles presence visualized by Oil 
Red O staining while the differentiated osteoblasts were detected by deposition of 
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extracellular calcium visualized by Von Kossa staining. Confocal images were acquired 
with an oil immersion objective (60x, 1.4 NA Plan-Apochromat; Olympus). Bright field 
images were acquired with a 40x objective (IX51 inverted microscope, Olympus). 
 
Immunosuppression assay 
Total splenocytes (SPL) were isolated from spleen of C57BL/6N mice. 200,000 SPL/well 
were seeded in a 96-well plate in complete RPMI supplemented with β-mercaptoethanol 50 
µM and co-cultured with BM- or A-MSC at ratio MSC:SPL of 1:2.5, 1:5, 1:10 and 1:50. 
Stimulation of T lymphocytes was induced by adding 1 µg/ml of purified Anti-Mouse CD3ε 
(BioLegend) and 0.5 µg/ml of purified Hamster Anti-Mouse CD28 (BD Biosciences) 
antibodies to the co-culture. After 48h, cells were incubated with [3H]thymidine 
(0.01µCi/µl) for 16h. A scintillation beta-counter was used to measure the incorporation of 
[3H]thymidine and results were expressed as percentage of SPL proliferation. 
 
MSC administration in experimental model of colitis 
Colitis was induced in eight- to twelve- week- old female C57BL/6 mice by administration 
of 3% DSS in drinking water ad libitum for 10 days. 3x106 of MSC/GFP-MSC were 
injected either intraperitoneally or subcutaneously at day 5 of DSS treatment. In selected 
experiments, MSC were implanted encapsulated into microcapsules of barium alginate at 
day 5 of DSS treatment in the peritoneum. Sorted MSCs were used in the experiments at 
passage ranking 7 to 10. Saline was administered as control. In parallel experiments, 4 
µg/mouse of Recombinant Mouse TSG-6 (R&D) was injected intraperitoneally to colitic 
mice starting from day 5 of DSS treatment to day 9. Survival, body weight and disease 
activity index (DAI) were evaluated daily as previously reported [209]. At day 10 damage 
to the mucosa of the colon was evaluated in vivo using the experimental Colorview 
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endoscopy system (Karl Storz Veterinary). Mice were then sacrificed, colon excised and 
colon length recorded. Colons were then Swiss-rolled and fixed in formalin 4% for 24 
hours, paraffin-embedded and sectioned (4µm). H&E staining was performed to evaluate 
tissue damage, which was scored by a blinded pathologist as described previously [210]. 
Animal experiments adhered to the requirements of the Commission Directive 86/609/EEC 
and to the Italian legislation (Decreto Legislativo 116; 27 January 1992). The studies were 
approved by the Animal Care and Use Committee (Istituto Clinico Humanitas, Milan, Italy). 
 
Encapsulation of MSC 
Encapsulation of MSC into microcapsules of barium alginate was performed in 
collaboration with Prof. Calafiore, Department of Internal Medicine, University of Perugia, 
Perugia, Italy, as previously described [211], resulting in the production of microcapsules 
measuring 400-500 µm in equatorial diameter, with no loss of MSC function and 
morphological properties, either in vitro and in vivo. The viability of cells entrapped within 
the capsules was assessed by fluorescein diacetate and ethidium bromide staining either 
before the implantation or 5 days after, when they were recovered from the peritoneal cavity 
of mice. 
 
Colons and structures digestion 
Colons and structures from both the peritoneal and subcutaneous cavity of colitic mice were 
recovered at day 10 of DSS treatment, rinsed in PBS w/o calcium and magnesium 
supplemented with penicillin, streptomycin and amphotericin B (Cambrex). Before 
digestion, colons were incubated 5 min at RT with 1mM dithiothreitol (DTT; Sigma) in 
HBSS w/o calcium and magnesium supplemented with antibiotics and cut into small pieces. 
Colon fragments and structures were digested for 1hour at 37°C with constantly agitation in 
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RPMI medium 1640 supplemented with 10% FCS, 20µg/ml DNASE I (ROCHE), 0.5 
mg/ml Collagenase NB4 Standard Grade (SERVA), 5mM CaCl2. Cell suspension obtained 
after digestion was then filtered through cell strainer with a mesh size of 100 µm, while 
tissue fragments were smashed on it. The cell strainer was carefully washed with RPMI 
medium 1640 supplemented with 10% FCS and the washing solution obtained was pulled 
together with the cell suspension and filtered through cell strainer with a mesh size of 70 
µm, centrifuged at 1500 rpm for 5 min at 4°C. After a final wash in PBS w/o calcium and 
magnesium supplemented with antibiotics, cells were ready for subsequent manipulations. 
 
Flow Cytometry 
MSC or cells coming from digestion of colons and structures were divided into FACS tubes 
at a density of 1x106 cells/tube, and incubated with the selected primary antibody in FACS 
buffer (PBS w/o calcium and magnesium supplemented with 1% FCS) for 20 min at 4°C. 
Table 1 shows in detail the list of the used antibodies. Alexa Fluor 647 streptavidin (1: 500; 
Invitrogen) was used to detect the expression levels of biotinylated antibody (Lineage Cell 
Detection Cocktail and CD31), while Alexa Fluor 647 goat anti-mouse (1:1500; Invitrogen) 
was employed for purified primary antibodies (CD106, CD90, CD34 and CD54). Viability 
of the cell suspension was assessed by the staining with Live/Dead Fixable Aqua Dead Cell 
Stain Kit (Invitrogen). Afterwards, all samples were fixed with 1% paraformaldehyde, while 
intracellular staining for FoxP3 was performed using the FoxP3 Staining Buffer Set 
(eBioscience). Samples were analysed on a FACScalibur flow cytometer (BD Biosciences). 
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Table 1. 
ANTIBODY	   ISOTYPE	  AND	  REACTIVITY	   DILUTION	   COMPANY	  
CD11b	   rat	  anti-­‐mouse	   1:80	   eBioscience	  
F4/80	   rat	  anti-­‐mouse	   1:10	   AbD	  Serotec	  
Ly/6G	   rat	  anti-­‐mouse	   1:30	   BD	  Pharmingen	  
CD45R/B220	   rat	  anti-­‐mouse	   1:50	   Biolegend	  
CD3	   rat	  anti-­‐mouse	   1:100	   BD	  Pharmingen	  
CD45	   rat	  anti-­‐mouse	   1:100	   BD	  Pharmingen	  
CD45.2	   mouse	  anti-­‐mouse	   1:300	   eBioscience	  
Lin	  Cell	  Det	  Cocktail	  biotin	   rat	  anti-­‐mouse	   1:10	   Miltenyi	  Biotec	  
CD31	  biotin	   rat	  anti-­‐mouse	   1:10	   BD	  Pharmingen	  
CD44	   rat	  anti-­‐mouse	   1:100	   Biolegend	  
CD106	  (VCAM-­1)	   rat	  anti-­‐mouse	   1:80	   BD	  Pharmingen	  
CD29	   Armenian	  Hamster	  anti-­‐mouse	   1:100	   Biolegend	  
CD90	   rat	  anti-­‐mouse	   1:50	   BD	  Pharmingen	  
CD54	  (ICAM-­1)	   Armenian	  Hamster	  anti-­‐mouse	   1:80	   BD	  Pharmingen	  
CD25	   rat	  anti-­‐mouse	   1:200	   eBioscience	  
CD4	   rat	  anti-­‐mouse	   1:200	   BD	  Biosciences	  
FoxP3	   rat	  anti-­‐mouse	   1:50	   eBioscience	  
Sca-­1	  (Ly-­6A/E)	   rat	  anti	  mouse	   1:100	   eBioscience	  
CD117	  (C-­kit)	   rat	  anti	  mouse	   1:20	   Miltenyi	  Biotec	  
CD34	   rat	  anti	  mouse	   1:50	   BD	  Biosciences	  
 
Immunohistochemistry  
Immunohistochemical staining for GFP was performed as previously reported [212]. Colons 
of colitic mice injected with 3x106 GFP-MSC 5 days after the beginning of DSS treatment 
were collected at day 10, fixed in 4% formalin and paraffin-embedded. Sections were cut at 
3 µm thickness, deparaffinized, hydrated and subsequently subjected to microwave epitope 
enhancement using citrate buffer 10 mM retrieval solution. A subsequent block for 
endogenous peroxidase with 0.3% H2O2 in block buffer (PBS w/o calcium and magnesium 
supplemented with 0.02% NP-40 (Calbiochem) and 1% Bovine Serum Albumine (BSA; 
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VWR International SRL) was performed. Sections were then incubated with the primary 
antibody anti-GFP, biotin-conjugated (1:500, o.n. at 4°C, Invitrogen) in block buffer. 
Detection was achieved using a standard streptavidin-biotin system (Vector Laboratories), 
and antigen localization was visualized with 3′-3-diamino benzidene (Vector Laboratories). 
	  
Immunofluorescence  
MSC were seeded on PolyLysine on glass coverslips as previously described and then fixed 
with pre-warmed paraformaldehyde (PFA) 2% for 10 min at 37°C. Cells were 
permeabilized with PBS containing 0.05% Tween20 (MERK), 3% BSA (VWR 
International SRL), 0.1% Triton X-100 (Sigma) for 20 min at RT and then blocked with 
PBS containing 0.05% Tween20; 3% BSA; 5% donkey serum (Jackson ImmunoResearch) 
or goat serum (DAKO) for 45 min at RT. Afterwards, MSC were incubated o.n at 4°C with 
the following primary antibodies: rat anti-mouse JAM-A (BV12, 1:20; a gift from E. 
Dejana, FIRC Institute of Molecular Oncology (IFOM), Milan, Italy), rat anti-mouse 
CD106 (1:80; BD Pharmingen), rabbit anti-mouse CD29 (1:100; Abcam) and rabbit anti-
mouse RAM-1 TSG-6 (1:250; produced by AJ Day’s group, Department of Biochemistry, 
University of Oxford, Oxford, United Kingdom). Cells were washed three times in PBS 
0.05% Tween 20 and then incubated for 30 min at RT with Alexa Fluor 647-conjugated 
donkey anti-rabbit or Alexa Fluor 594-conjugated goat anti-rat antibodies (1:1000; 
Invitrogen), followed by incubation for 10 min at RT with DAPI (1:25000; Invitrogen). 
Finally, glass coverslip were mounted with Prolong* Gold Antifade Reagent (Invitrogen). 
 
Whole Mount staining 
Whole mount staining was performed in colon of healthy and colitic mice, injected 
intraperitoneally at day 5 with MSC pre-stained with DilC18(3)-DS (Invitrogen). Briefly, 
MSC were collected, resuspended in PBS w/o calcium and magnesium supplemented with 
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0.1% FCS and 1µM DilC18(3)-DS, incubated first 5 min at 37°C and then 15 min at 4°C 
immediately before the injection. 24, 48 and 72 hours after the injection, mice were 
perfused with 1% PFA, colons were collected, opened and cut into three pieces (rectal, 
proximal and distal colons), mounted on a hard silicon base and incubated with rat anti-
mouse CD31 (1:150; BD Pharmingen) in PBS containing 2% BSA; 0.01% NaN3; 0.3% 
Triton X-100; 5% goat serum o.n. at 4°C.  Afterwards, colons were incubated with Alexa 
Fluor 488-conjugated goat anti-rat (1:1000; Invitrogen) o.n. at 4°C and mounted with 
Prolong* Gold Antifade Reagent (Invitrogen). The same protocol was used for whole mount 
staining of colons, in which GFP-MSC were injected intraperitoneally at day 5 of DSS 
treatment. After 5 days from the injection, mice were sacrificed, structures were recovered, 
fixed in PFA 4% o.n. at 4°C and stained with rat anti-mouse CD68 (1:200; BD 
Pharmingen), rabbit anti-mouse CD3 (1:100; DAKO) and rabbit anti-mouse TSG-6 o.n. at 
4°C. A final incubation with Alexa Fluor 594-conjugated chicken anti-rat and/or Alexa 
Fluor 647-conjugated donkey anti-rabbit (1:1000; Invitrogen) o.n. at 4°C was performed 
before mounting the structures with Prolong* Gold Antifade Reagent (Invitrogen). 
 
Real-Time PCR 
RNA from MSC and macrophages was extracted using the commercially available RNeasy 
Mini kit (Qiagen), while RNA from colons and MLNs was extracted using RNeasy Lipid 
Tissue Mini kit (Qiagen) according to manufacturer’s instructions. First-strand cDNA 
synthesis (High-Capacity cDNA Reverse Transcription Kit; Applied Biosystems) from 2 µg 
of total RNA was conducted according to the manufacturer’s instructions. Then quantitative 
real-time PCR was performed using SyBr Green PCR Master Mix (Applied Biosystems) or 
TaqMan Gene Expression Master Mix (Applied Biosystems) and detected with 7900HT 
Sequence Detection System (Applied Biosystems). Primer sequences or probe assay ID/part 
numbers are reported in Table 2a and 2b, respectively. The relative mRNA abundance of all 
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transcripts was calculated as 2-ΔCt (where ΔCt is equal to Ct sample - Ct housekeeping) 
analysed over the total amount of GAPDH or Actin. 
 
Table 2a. 
GENE	   PRIMER	  SEQUENCES	  
CCR1	   Forward,	  5’-­‐	  CTG	  CCC	  CCC	  CTG	  TAT	  TCT	  CT-­‐3’	  
Reverse,	  5’-­‐	  GAC	  ATT	  GCC	  CAC	  CAC	  TCC	  A-­‐3’	  
CCR2	   Forward,	  5’-­‐	  CTA	  CGA	  TGA	  TGG	  TGA	  GCC	  TTG	  TC-­‐3’	  
Reverse,	  5’-­‐	  AGC	  TCC	  AAT	  TTG	  CTT	  CAC	  ACT	  G-­‐3’	  
CCR3	   Forward,	  5’-­‐	  AGT	  GGG	  CAC	  CAC	  CCT	  GTG-­‐3’	  
Reverse,	  5’-­‐	  GCC	  ATG	  ACC	  CCA	  GCT	  CTT	  T-­‐3’	  
CCR4	   Forward,	  5’-­‐	  ACG	  AAA	  GCA	  TGC	  CAA	  AGC	  C-­‐3’	  
Reverse,	  5’-­‐	  CCC	  CAA	  ATG	  CCT	  TGA	  TAC	  CTT-­‐3’	  
CCR5	   Forward,	  5’-­‐	  TCA	  GCA	  CCC	  TGC	  CAA	  AAA	  AT-­‐3’	  
Reverse,	  5’-­‐	  CAG	  GAG	  CTG	  AGC	  CGC	  AAT-­‐3’	  
CCR6	   Forward,	  5’-­‐	  GGC	  CTG	  TAT	  CAG	  CAT	  GGA	  CC-­‐3’	  
Reverse,	  5’-­‐	  GAT	  TTG	  GTT	  GCC	  TGG	  ACG	  AT-­‐3’	  
CCR7	   Forward,	  5’-­‐	  TGG	  TGG	  TGG	  CTC	  TCC	  TTG	  TC-­‐3’	  
Reverse,	  5’-­‐	  CCT	  CAT	  CTT	  GGC	  AGA	  GAA	  GCA	  CA-­‐3’	  
CCR8	   Forward,	  5’-­‐	  ACC	  CTG	  ATT	  TCT	  TCA	  CCG	  CC-­‐3’	  
Reverse,	  5’-­‐	  TGC	  CCC	  TGA	  GGA	  GGA	  ACT	  CT-­‐3’	  
CCR9	   Forward,	  5’-­‐	  TGA	  TGC	  CCA	  CAG	  AAC	  TCA	  CAA-­‐3’	  
Reverse,	  5’-­‐	  TGA	  AGT	  CAT	  CAA	  ACA	  TGC	  CAG	  G-­‐3’	  
CXCR1	   Forward,	  5’-­‐	  TCC	  TGA	  GGT	  GAC	  TTT	  GAG	  AAA	  G-­‐3’	  
Reverse,	  5’-­‐	  GGC	  AGC	  ATT	  CCC	  GTG	  ATA	  TTT-­‐3’	  
CXCR2	   Forward,	  5’-­‐	  GTC	  ATC	  TTC	  GCT	  GTC	  GTC	  CTT-­‐3’	  
Reverse,	  5’-­‐	  GTT	  GTA	  GGG	  CAG	  CCA	  GCA	  G-­‐3’	  
CXCR3	   Forward,	  5’-­‐	  TGG	  AAA	  ACA	  GCA	  CCT	  CTC	  CC-­‐3’	  
Reverse,	  5’-­‐	  AGA	  AGT	  CGC	  TCT	  CGT	  TTT	  CCC-­‐3’	  
CXCR4	   Forward,	  5’-­‐	  CCT	  GCT	  TCC	  GGG	  ATG	  AAA	  A-­‐3’	  
Reverse,	  5’-­‐	  TGG	  TGG	  GCA	  GGA	  AGA	  TCC	  TAT-­‐3’	  
CXCR5	   Forward,	  5’-­‐	  ACT	  CGG	  AGC	  TCA	  ACC	  GAG	  AC-­‐3’	  
Reverse,	  5’-­‐	  AAG	  GTC	  GGC	  TAC	  TGC	  GAG	  G-­‐3’	  
CXCR6	   Forward,	  5’-­‐	  TAC	  GAT	  GGG	  CAC	  TAC	  GAG	  GG-­‐3’	  
Reverse,	  5’-­‐	  ATC	  ACT	  GGA	  ATT	  GTT	  GAA	  GAG	  CC-­‐3’	  
CXCR7	   Forward,	  5’-­‐	  TGT	  AAC	  AGC	  AGC	  GAC	  TGC	  ATT-­‐3’	  
Reverse,	  5’-­‐	  CAT	  GGT	  GGG	  ACA	  CTG	  CAC	  AG-­‐3’	  
XCR1	   Forward,	  5’-­‐	  TCT	  TCA	  CCG	  TCG	  TGG	  TAG	  CA-­‐3’	  
Reverse,	  5’-­‐	  TGA	  GGT	  TGT	  AGG	  GAG	  CCC	  AG-­‐3’	  
CX3CR1	   Forward,	  5’-­‐	  CTG	  TCC	  GTC	  TTC	  TAC	  GCC	  CT-­‐3’	  
Reverse,	  5’-­‐	  CAG	  ATT	  TCC	  CAC	  CAG	  ACC	  GA-­‐3’	  
IDO	  1	   Forward,	  5’-­‐	  TGG	  CGT	  ATG	  TGT	  GGA	  ACC	  G-­‐3’	  
Reverse,	  5’-­‐	  CTC	  GCA	  GTA	  GGG	  AAC	  AGC	  AA-­‐3’	  
IDO	  2	   Forward,	  5’-­‐	  AAG	  GCC	  AAC	  CCC	  AAA	  AGG	  TG-­‐3’	  
Reverse,	  5’-­‐	  ACC	  AGG	  ATA	  GGC	  GGG	  AGT	  C-­‐3’	  
TSG-­6	   Forward,	  5’-­‐	  GGC	  TGG	  CAG	  ATA	  CAA	  GCT	  CA-­‐3’	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Reverse,	  5’-­‐	  TCA	  AAT	  TCA	  CAT	  ACG	  GCC	  TTG	  G-­‐3’	  
TGF-­β	   Forward,	  5’-­‐	  ATC	  CTC	  AAG	  TTG	  CAC	  CCT	  TAT	  CT-­‐3’	  
Reverse,	  5’-­‐	  AAA	  GAG	  CCT	  TCG	  GTG	  GAT	  TGC-­‐3’	  
IL-­10	   Forward,	  5’-­‐	  GCT	  CTT	  ACT	  GAC	  TGG	  CAT	  GAG-­‐3’	  
Reverse,	  5’-­‐	  CGC	  AGC	  TCT	  AGG	  AGC	  ATG	  TG-­‐3’	  
IFN-­γ	   Forward,	  5’-­‐	  GGA	  TGG	  TGA	  CAT	  GAA	  AAT	  CCT	  GC-­‐3’	  
Reverse,	  5’-­‐	  TGC	  TGA	  TGG	  CCT	  GAT	  TGT	  CTT-­‐3’	  
IL-­6	   Forward,	  5’-­‐	  TAG	  TCC	  TTC	  CTA	  CCC	  CAA	  TTT	  CC-­‐3’	  
Reverse,	  5’-­‐	  TTG	  GTC	  CTT	  AGC	  CAC	  TCC	  TTC-­‐3’	  
IL-­4	   Forward,	  5’-­‐	  CCA	  TAT	  CCA	  CGG	  ATG	  CGA	  CAA-­‐3’	  
Reverse,	  5’-­‐	  CCT	  CGT	  TCA	  AAA	  TGC	  CGA	  TGA	  T-­‐3’	  
IL-­5	   Forward,	  5’-­‐	  ACT	  GTC	  CGT	  GGG	  GGT	  ACT	  G-­‐3’	  
Reverse,	  5’-­‐	  AGG	  AAC	  TCT	  TGC	  AGG	  TAA	  TCC	  A-­‐3’	  
IL-­13	   Forward,	  5’-­‐	  CAG	  CCT	  CCC	  CGA	  TAC	  CAA	  AAT-­‐3’	  
Reverse,	  5’-­‐	  GCG	  AAA	  CAG	  TTG	  CTT	  TGT	  GTA	  G-­‐3’	  
IL-­17a	   Forward,	  5’-­‐	  TCA	  GCG	  TGT	  CCA	  AAC	  ACT	  GAG-­‐3’	  
Reverse,	  5’-­‐	  GAC	  TTT	  GAG	  GTT	  GAC	  CTT	  CAC	  AT-­‐3’	  
MMP12	   Forward,	  5’-­‐	  GAG	  TCC	  AGC	  CAC	  CAA	  CAT	  TAC-­‐3’	  
Reverse,	  5’-­‐	  GCG	  AAG	  TGG	  GTC	  AAA	  GAC	  AG-­‐3’	  
GAPDH	   Forward,	  5’-­‐	  AGG	  TCG	  GTG	  TGA	  ACG	  GAT	  TTG-­‐3’	  
Reverse,	  5’-­‐	  TGT	  AGA	  CCA	  TGT	  AGT	  TGA	  GGT	  CA-­‐3’	  
 
Table 2b. 
GENE	   ASSAY	  ID/	  PART	  NUMBER	   COMPANY	  
MMP3	   Mm00440295_m1	   Applied	  Biosystems	  
MMP9	   Mm00442991_m1	   Applied	  Biosystems	  
MCP1	  (CCL2)	   Mm00441242_m1	   Applied	  Biosystems	  
MIP1α	  (CCL3)	   Mm00441259_g1	   Applied	  Biosystems	  
Actin	  (ACTB)	   4352341E	   Applied	  Biosystems	  
 
Structures and MSC Organ Culture 
Structures were recovered from the peritoneal cavity of colitic mice 48 and 72h after MSC 
injection. The structures were carefully washed in cold PBS supplemented with antibiotics 
and then incubated at 37°C and 5% CO2 in DMEM medium supplemented with 0.1% FCS 
and antibiotics. After 24 hours, supernatant fluid was collected, centrifuged and stored at -
20°C for subsequent analysis, while cells that had detached from the structures and adhered 
to the dish surface were collected and analysed by flow cytometry.  In parallel experiments, 
MSC were seeded at a density of 10000 cells/cm2 in a 96-well plate in complete MSC 
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expansion medium and when confluence was reached, supernatant fluid was collected, 
centrifuged and store at -20°C. Since MSC expansion medium contained unknown growth 
factors and cytokines, an aliquot of this culture medium was used as negative control in 
further analysis. 
 
Bio-Plex Assay and ELISA 
The concentration of TSG-6 was evaluated in the supernatants obtained from Organ Culture 
of MSC and in the serum of healthy and colitic mice injected or not with MSC, 48 and 72 
hours after the injection. The quantification was assessed following the manufacture’s 
instruction of the ELISA kit for Tumor Necrosis Factor Alpha Induced Protein 6 (TNFaIP6) 
(Life Science Inc). In parallel experiments, serum samples were obtained from healthy and 
colitic mice injected with either MSC, Recombinant Mouse TSG-6, or saline and sacrificed 
5 days after the injection. The concentration of IL-4, IL-5, IL-6, IL-10, IL-12(p40), IL-
12(p70), IL-13, IL-17a, IFN-γ, KC, MCP-1 (MCAF) and TNF-α was detected using Bio-
Plex Mouse Cytokine Group I 12-plex Assay (Biorad). Naïve mice were used as negative 
control. Finally, protein colon lysates of mice injected with either BM-or A-MSC were 
prepared by homogenization in Lysis Buffer (50mM Tris-HCl pH 7.4; 1mM EDTA pH 8; 
150mM NaCl; 0.1% Triton X-100; 1X Protease Inhibitor cocktail (Roche); 1X PMSF 
(SIGMA) with TissueLyser II (Qiagen) and analysed for the concentration of IL-6, TNF-α, 
IFN-γ, Il-10, RANTES (CCL5), MIP-1α (CCL3) and MCP-1 (CCL2) using commercially 
available ELISA kits (R&D). 
 
Western Blot 
Protein lysates were collected from MSC, as previously described. Protein samples were 
separated by 10% SDS-PAGE under reducing conditions by using Tris-glycine running 
buffer. After electrophoresis, proteins were transferred to polyvinylidene fluoride (PVDF) 
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membrane (Biorad). Membrane was blocked in 5% milk in PBS for 1 hour and then 
incubated with rabbit anti-mouse RAM-1 TSG-6 (1:500) in PBS supplemented with 0.1% 
Tween20 and 5% milk o.n. at 4°C. Membrane was washed and incubated first for 1 hour 
with HRP-conjugated anti-rabbit IgG (VWR International) in PBS containing 0.1% 
Tween20 and then with Immobilon Western Chemiluminescent HRP Substrate (Millipore) 
for 1 minute. Antigen-antibody complexes were detected by using ChemiDoc XRS 
(Biorad). MMP3 and MMP9 protein levels were analysed on colon lysates of healthy and 
colitic mice injected with either MSC, Recombinant Murine TSG-6 or saline using the 
following antibodies: rabbit anti-mouse MMP3 (1:1000; abcam) or rabbit anti-mouse 
MMP9 (1:800; Aviva Systems Biology) as primary antibodies; HRP-conjugated anti-rabbit 
IgG as secondary antibody. The filter was then stripped with buffer Restore (Pierce) and 
reprobed with an anti–β-actin antibody to control for protein loading. 
 
Analysis of collagen deposition within the structures  
Structures were recovered from the peritoneal cavity of colitic mice, fixed in PFA 4% o.n. at 
4°C and mounted with Prolong* Gold Antifade Reagent on agarose-coated glass slide to 
maintained their 3D organization. Type I collagen deposition inside structures was 
visualized by Two Photon Excitation Microscopy (TPEM) and Second Harmonic 
Generation (SHG) signals for every chosen layer was recorded. The received pictures of 
type I collagen fibres were then assembled and analysed. The excitation wavelength of two 
photon laser was tuned to 820 nm. Alternatively, structure frozen sections of 20µm 
thickness were fixed in 37% formaldehyde and stained with Picro-Sirius Red to visualize 
collagen type I and III fibers. Briefly, sections were incubated with Picro-Sirius Red stain 
solution (0.1% direct red 80 (Sigma) and 0.1% fast green FCF (Sigma) dissolved in 
saturated aqueous picric acid (1.2% picric acid (Sigma) in water) for 60 min at RT. After 
rinsing in distilled water and HCl 0.01M (PH=2) for 2 min at RT, sections were dehydrated 
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and mounted in xylene. Bright field images were acquired with a 4x and 40x objectives 
(IX51 inverted microscope, Olympus). 
 
Statistical Analysis 
Data were analysed using GraphPad software. The Student t tast was used for comparisons 
between groups. Statistical significance was set at P<0.05. 
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